Alarm characterization for analyte monitoring devices and systems

Description

BACKGROUND

The detection of the level of analytes, such as glucose, lactate, oxygen, and the like, in certain individuals is vitally important to their health. For example, the monitoring of glucose is particularly important to individuals with diabetes. Diabetics may need to monitor glucose levels to determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose in their bodies.

SUMMARY

Embodiments of the present disclosure include determining a rate of occurrence of a glycemic excursion event, determining a frequency of an alarm activation associated with the glycemic excursion event, determining an analyte level associated with the alarm activation, and setting an alarm parameter based on one or more of the determined rate of occurrence of the glycemic excursion event, the frequency of the alarm activation associated with the glycemic excursion event or the determined analyte level.

In a further aspect, there is provided an interface component, one or more processors operatively coupled to the interface component, and a memory for storing instructions which, when executed by the one or more processors, causes the one or more processors to determine a rate of occurrence of a glycemic excursion event, determine a frequency of an alarm activation associated with the glycemic excursion event, determine an analyte level associated with the alarm activation, and set an alarm parameter based on one or more of the determined rate of occurrence of the glycemic excursion event, the frequency of the alarm activation associated with the glycemic excursion event or the determined analyte level.

These and other features, objects and advantages of the present disclosure will become apparent to those persons skilled in the art upon reading the details of the present disclosure as more fully described below.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a block diagram of an embodiment of a data monitoring and management system according to the present disclosure;

FIG. 2 shows a block diagram of an embodiment of the transmitter unit of the data monitoring and management system of FIG. 1;

FIG. 3 shows a block diagram of an embodiment of the receiver/monitor unit of the data monitoring and management system of FIG. 1;

FIG. 4 shows a schematic diagram of an embodiment of an analyte sensor according to the present disclosure;

FIGS. 5A-5B illustrate a perspective view and a cross sectional view, respectively of another embodiment of an analyte sensor;

FIG. 6 is a flowchart illustrating a routine for establishing or setting an alarm parameter based on glycemic excursion events in accordance with one embodiment of the present disclosure; and

FIG. 7 is a flowchart illustrating a routine for determining a rate of occurrence of a glycemic excursion event in accordance with one embodiment of the present disclosure.

INCORPORATION BY REFERENCE

The following patents, applications and/or publications are incorporated herein by reference for all purposes: U.S. Pat. Nos. 4,545,382; 4,711,245; 5,262,035; 5,262,305; 5,264,104; 5,320,715; 5,509,410; 5,543,326; 5,593,852; 5,601,435; 5,628,890; 5,820,551; 5,822,715; 5,899,855; 5,918,603; 6,071,391; 6,103,033; 6,120,676; 6,121,009; 6,134,461; 6,143,164; 6,144,837; 6,161,095; 6,175,752; 6,270,455; 6,284,478; 6,299,757; 6,338,790; 6,377,894; 6,461,496; 6,503,381; 6,514,460; 6,514,718; 6,540,891; 6,560,471; 6,579,690; 6,591,125; 6,592,745; 6,600,997; 6,605,200; 6,605,201; 6,616,819; 6,618,934; 6,650,471; 6,654,625; 6,676,816; 6,676,819; 6,730,200; 6,736,957; 6,746,582; 6,749,740; 6,764,581; 6,773,671; 6,881,551; 6,893,545; 6,932,892; 6,932,894; 6,942,518; 7,167,818; and 7,299,082; U.S. Published Application Nos. 2004/0186365, now U.S. Pat. No. 7,811,231; 2005/0182306, now U.S. Pat. No. 8,711,183; 2007/0056858, now U.S. Pat. No. 8,298,389; 2007/0068807, now U.S. Pat. No. 7,846,311; 2007/0227911, now U.S. Pat. No. 7,887,682; 2007/0233013; 2008/0081977, now U.S. Pat. No. 7,618,369; 2008/0161666; and 2009/0054748, now U.S. Pat. No. 7,885,698; U.S. patent application Ser. No. 11/396,135, now U.S. Pat. Nos. 7,620,438, 11/537,984, 12/131,012; 12/242,823, now U.S. Pat. No. 8,219,173; and Ser. No. 12/363,712, now U.S. Pat. No. 8,346,335; and U.S. Provisional Application Ser. Nos. 61/149,639; 61/155,889; 61/155,891; 61/155,893; 61/165,499; 61/230,686; 61/227,967 and 61/238,461.

DETAILED DESCRIPTION

Before the present disclosure is described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges as also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.

The figures shown herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity.

Generally, embodiments of the present disclosure relate to methods and devices for detecting at least one analyte such as glucose in body fluid. Embodiments relate to the continuous and/or automatic in vivo monitoring of the level of one or more analytes using a continuous analyte monitoring system that includes an analyte sensor at least a portion of which is to be positioned beneath a skin surface of a user for a period of time and/or the discrete monitoring of one or more analytes using an in vitro blood glucose (“BG”) meter and an analyte test strip. Embodiments include combined or combinable devices, systems and methods and/or transferring data between an in vivo continuous system and a BG meter system.

Accordingly, embodiments include analyte monitoring devices and systems that include an analyte sensor—at least a portion of which is positionable beneath the skin of the user—for the in vivo detection, of an analyte, such as glucose, lactate, and the like, in a body fluid. Embodiments include wholly implantable analyte sensors and analyte sensors in which only a portion of the sensor is positioned under the skin and a portion of the sensor resides above the skin, e.g., for contact to a transmitter, receiver, transceiver, processor, etc. The sensor may be, for example, subcutaneously positionable in a patient for the continuous or periodic monitoring of a level of an analyte in a patient's interstitial fluid. For the purposes of this description, continuous monitoring and periodic monitoring will be used interchangeably, unless noted otherwise. The sensor response may be correlated and/or converted to analyte levels in blood or other fluids. In certain embodiments, an analyte sensor may be positioned in contact with interstitial fluid to detect the level of glucose, which detected glucose may be used to infer the glucose level in the patient's bloodstream. Analyte sensors may be insertable into a vein, artery, or other portion of the body containing fluid. Embodiments of the analyte sensors of the subject disclosure may be configured for monitoring the level of the analyte over a time period which may range from minutes, hours, days, weeks, or longer.

Of interest are analyte sensors, such as glucose sensors, that are capable of in vivo detection of an analyte for about one hour or more, e.g., about a few hours or more, e.g., about a few days of more, e.g., about three days or more, e.g., about five days or more, e.g., about seven days or more, e.g., about several weeks or at least one month. Future analyte levels may be predicted based on information obtained, e.g., the current analyte level at time t0, the rate of change of the analyte, etc. Predictive alarms may notify the user of a predicted analyte level that may be of concern in advance of the user's analyte level reaching the future level. This provides the user an opportunity to take corrective action.

FIG. 1 shows a data monitoring and management system such as, for example, an analyte (e.g., glucose) monitoring system 100 in accordance with certain embodiments. Embodiments of the subject disclosure are further described primarily with respect to glucose monitoring devices and systems, and methods of glucose detection, for convenience only and such description is in no way intended to limit the scope of the disclosure. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes at the same time or at different times.

Analytes that may be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketone bodies, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored. In those embodiments that monitor more than one analyte, the analytes may be monitored at the same or different times.

The analyte monitoring system 100 includes a sensor 101, a data processing unit 102 connectable to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the data processing unit 102 via a communication link 103. In certain embodiments, the primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 to evaluate or otherwise process or format data received by the primary receiver unit 104. The data processing terminal 105 may be configured to receive data directly from the data processing unit 102 via a communication link which may optionally be configured for bi-directional communication. Further, the data processing unit 102 may include a transmitter or a transceiver to transmit and/or receive data to and/or from the primary receiver unit 104 and/or the data processing terminal 105 and/or optionally the secondary receiver unit 106.

Also shown in FIG. 1 is an optional secondary receiver unit 106 which is operatively coupled to the communication link and configured to receive data transmitted from the data processing unit 102. The secondary receiver unit 106 may be configured to communicate with the primary receiver unit 104, as well as the data processing terminal 105. The secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in certain embodiments the secondary receiver unit 106 may be a de-featured receiver as compared to the primary receiver, i.e., the secondary receiver may include a limited or minimal number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may include a smaller (in one or more, including all, dimensions), compact housing or embodied in a device such as a wrist watch, arm band, etc., for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functions and features as the primary receiver unit 104. The secondary receiver unit 106 may include a docking portion to be mated with a docking cradle unit for placement by, e.g., the bedside for night time monitoring, and/or a bi-directional communication device. A docking cradle may recharge a powers supply.

Only one sensor 101, data processing unit 102 and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include more than one sensor 101 and/or more than one data processing unit 102, and/or more than one data processing terminal 105. Multiple sensors may be positioned in a patient for analyte monitoring at the same or different times. In certain embodiments, analyte information obtained by a first positioned sensor may be employed as a comparison to analyte information obtained by a second sensor. This may be useful to confirm or validate analyte information obtained from one or both of the sensors. Such redundancy may be useful if analyte information is contemplated in critical therapy-related decisions. In certain embodiments, a first sensor may be used to calibrate a second sensor.

The analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each component may be configured to be uniquely identified by one or more of the other components in the system so that communication conflict may be readily resolved between the various components within the analyte monitoring system 100. For example, unique IDs, communication channels, and the like, may be used.

In certain embodiments, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to at least periodically sample the analyte level of the user and convert the sampled analyte level into a corresponding signal for transmission by the data processing unit 102. The data processing unit 102 is coupleable to the sensor 101 so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously. The data processing unit may include a fixation element such as adhesive or the like to secure it to the user's body. A mount (not shown) attachable to the user and mateable with the data processing unit 102 may be used. For example, a mount may include an adhesive surface. The data processing unit 102 performs data processing functions, where such functions may include, but are not limited to, filtering and encoding of data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103. In one embodiment, the sensor 101 or the data processing unit 102 or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.

In certain embodiments, the primary receiver unit 104 may include an analog interface section including an RF receiver and an antenna that is configured to communicate with the data processing unit 102 via the communication link 103, and a data processing section for processing the received data from the data processing unit 102 such as data decoding, error detection and correction, data clock generation, data bit recovery, etc., or any combination thereof.

In operation, the primary receiver unit 104, in certain embodiments, is configured to synchronize with the data processing unit 102 to uniquely identify the data processing unit 102, based on, for example, an identification information of the data processing unit 102, and thereafter, to periodically receive signals transmitted from the data processing unit 102 associated with the monitored analyte levels detected by the sensor 101.

Referring again to FIG. 1, the data processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs), telephone such as a cellular phone (e.g., a multimedia and Internet-enabled mobile phone such as an iPhone or similar phone), mp3 player, pager, and the like), drug delivery device, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving, updating, and/or analyzing data corresponding to the detected analyte level of the user.

The data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the primary receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, the primary receiver unit 104 may be configured to integrate an infusion device therein so that the primary receiver unit 104 is configured to administer insulin (or other appropriate drug) therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the data processing unit 102. An infusion device may be an external device or an internal device (wholly implantable in a user).

In certain embodiments, the data processing terminal 105, which may include an insulin pump, may be configured to receive the analyte signals from the data processing unit 102, and thus, incorporate the functions of the primary receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In certain embodiments, the communication link 103, as well as one or more of the other communication interfaces shown in FIG. 1, may use one or more of: an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements), while avoiding potential data collision and interference.

FIG. 2 shows a block diagram of an embodiment of a data processing unit of the data monitoring and detection system shown in FIG. 1. User input 202 and/or interface components may be included or a data processing unit may be free of user input and/or interface components. In certain embodiments, one or more application specific integrated circuits (ASIC) may be used to implement one or more functions or routines associated with the operations of the data processing unit (and/or receiver unit) using for example one or more state machines and buffers.

Further shown in FIG. 2 are serial communication section 205 and an RF transmitter 206, each of which is also operatively coupled to the transmitter processor 204. Also shown in FIG. 2 is a dedicated link 209 from the analog interface 201 to serial communication section 205. Moreover, a power supply 207, such as a battery, may also be provided in the data processing unit 102 to provide the necessary power for the data processing unit 102. Additionally, as can be seen from the Figure, clock 208 may be provided to, among others, supply real time information to the transmitter processor 204.

As can be seen in the embodiment of FIG. 2, the sensor 101 (FIG. 1) includes four contacts, three of which are electrodes—working electrode (W) 210, reference electrode (R) 212, and counter electrode (C) 213, each operatively coupled to the analog interface 201 of the data processing unit 102. This embodiment also shows optional guard contact (G) 211. Fewer or greater electrodes may be employed. For example, the counter and reference electrode functions may be served by a single counter/reference electrode, there may be more than one working electrode and/or reference electrode and/or counter electrode, etc.

Referring yet again to FIG. 2, a temperature measurement section 203 of the data processing unit 102 is configured to monitor the temperature of the skin near the sensor insertion site. The temperature reading may be used to adjust the analyte readings obtained from the analog interface 201. Also shown is a leak detection circuit 214 coupled to the guard contact (G) 211 and the processor 204 in the data processing unit 102 of the analyte monitoring system 100. The leak detection circuit 214 may be configured to detect leakage current in the sensor 101 to determine whether the measured sensor data are corrupt or whether the measured data from the sensor 101 is accurate. Such detection may trigger a notification to the user.

FIG. 3 is a block diagram of an embodiment of a receiver/monitor unit such as the primary receiver unit 104 of the data monitoring and management system shown in FIG. 1. The primary receiver unit 104 includes one or more of: a blood glucose test strip interface 301, an RF receiver 302, an input 303, a temperature detection section 304, and a clock 305, each of which is operatively coupled to a processing and storage section 307. The primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308. Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307. Moreover, also shown are a receiver serial communication section 309, and an output 310, each operatively coupled to the processing and storage unit 307. The receiver may include user input and/or interface components or may be free of user input and/or interface components.

In certain embodiments, the test strip interface 301 includes a glucose level testing portion to receive a blood (or other body fluid sample) glucose test or information related thereto. For example, the interface may include a test strip port to receive a glucose test strip. The device may determine the glucose level of the test strip, and optionally display (or otherwise notice) the glucose level on the output 310 of the primary receiver unit 104. Any suitable test strip may be employed, e.g., test strips that only require a very small amount (e.g., one microliter or less, e.g., 0.5 microliter or less, e.g., 0.1 microliter or less), of applied sample to the strip in order to obtain accurate glucose information, e.g. FreeStyle® blood glucose test strips from Abbott Diabetes Care Inc. Glucose information obtained by the in vitro glucose testing device may be used for a variety of purposes, computations, etc. For example, the information may be used to calibrate sensor 101, confirm results of the sensor 101 to increase the confidence thereof (e.g., in instances in which information obtained by sensor 101 is employed in therapy related decisions), etc.

In further embodiments, the data processing unit 102 and/or the primary receiver unit 104 and/or the secondary receiver unit 106, and/or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a blood glucose meter. In further embodiments, a user manipulating or using the analyte monitoring system 100 (FIG. 1) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, voice commands, and the like) incorporated in the one or more of the data processing unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105.

Additional detailed descriptions are provided in U.S. Pat. Nos. 5,262,035; 5,264,104; 5,262,305; 5,320,715; 5,593,852; 6,175,752; 6,650,471; 6,746,582, and in application Ser. No. 10/745,878 filed Dec. 26, 2003, now U.S. Pat. No. 7,811,231, entitled “Continuous Glucose Monitoring System and Methods of Use”, each of which is incorporated herein by reference.

FIG. 4 schematically shows an embodiment of an analyte sensor in accordance with the present disclosure. This sensor embodiment includes electrodes 401, 402 and 403 on a base 404. Electrodes (and/or other features) may be applied or otherwise processed using any suitable technology, e.g., chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, ablating (e.g., laser ablation), painting, dip coating, etching, and the like. Materials include, but are not limited, to aluminum, carbon (such as graphite), cobalt, copper, gallium, gold, indium, iridium, iron, lead, magnesium, mercury (as an amalgam), nickel, niobium, osmium, palladium, platinum, rhenium, rhodium, selenium, silicon (e.g., doped polycrystalline silicon), silver, tantalum, tin, titanium, tungsten, uranium, vanadium, zinc, zirconium, mixtures thereof, and alloys, oxides, or metallic compounds of these elements.

The sensor may be wholly implantable in a user or may be configured so that only a portion is positioned within (internal) a user and another portion outside (external) a user. For example, the sensor 400 may include a portion positionable above a surface of the skin 410, and a portion positioned below the skin. In such embodiments, the external portion may include contacts (connected to respective electrodes of the second portion by traces) to connect to another device also external to the user such as a transmitter unit. While the embodiment of FIG. 4 shows three electrodes side-by-side on the same surface of base 404, other configurations are contemplated, e.g., fewer or greater electrodes, some or all electrodes on different surfaces of the base or present on another base, some or all electrodes stacked together, electrodes of differing materials and dimensions, etc.

FIG. 5A shows a perspective view of an embodiment of an electrochemical analyte sensor 500 having a first portion (which in this embodiment may be characterized as a major portion) positionable above a surface of the skin 510, and a second portion (which in this embodiment may be characterized as a minor portion) that includes an insertion tip 530 positionable below the skin, e.g., penetrating through the skin and into, e.g., the subcutaneous space 520, in contact with the user's biofluid such as interstitial fluid. Contact portions of a working electrode 501, a reference electrode 502, and a counter electrode 503 are positioned on the portion of the sensor 500 situated above the skin surface 510. Working electrode 501, a reference electrode 502, and a counter electrode 503 are shown at the second section and particularly at the insertion tip 530. Traces may be provided from the electrode at the tip to the contact, as shown in FIG. 5A. It is to be understood that greater or fewer electrodes may be provided on a sensor. For example, a sensor may include more than one working electrode and/or the counter and reference electrodes may be a single counter/reference electrode, etc.

FIG. 5B shows a cross sectional view of a portion of the sensor 500 of FIG. 5A. The electrodes 501, 502 and 503, of the sensor 500 as well as the substrate and the dielectric layers are provided in a layered configuration or construction. For example, as shown in FIG. 5B, in one aspect, the sensor 500 (such as the sensor 101FIG. 1), includes a substrate layer 504, and a first conducting layer 501, such as carbon, gold, etc., disposed on at least a portion of the substrate layer 504, and which may provide the working electrode. Also shown disposed on at least a portion of the first conducting layer 501 is a sensing layer 508.

A first insulation layer such as a first dielectric layer 505 is disposed or layered on at least a portion of the first conducting layer 501, and further, a second conducting layer 509 may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) 505. As shown in FIG. 5B, the second conducting layer 509 may provide the reference electrode 502, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl), gold, etc.

A second insulation layer 506 such as a dielectric layer in one embodiment may be disposed or layered on at least a portion of the second conducting layer 509. Further, a third conducting layer 503 may provide the counter electrode 503. It may be disposed on at least a portion of the second insulation layer 506. Finally, a third insulation layer 507 may be disposed or layered on at least a portion of the third conducting layer 503. In this manner, the sensor 500 may be layered such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer). The embodiment of FIGS. 5A and 5B show the layers having different lengths. Some or all of the layers may have the same or different lengths and/or widths.

In certain embodiments, some or all of the electrodes 501, 502, 503 may be provided on the same side of the substrate 504 in the layered construction as described above, or alternatively, may be provided in a co-planar manner such that two or more electrodes may be positioned on the same plane (e.g., side-by side (e.g., parallel) or angled relative to each other) on the substrate 504. For example, co-planar electrodes may include a suitable spacing there between and/or include dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in certain embodiments, one or more of the electrodes 501, 502, 503 may be disposed on opposing sides of the substrate 504. In such embodiments, contact pads may be on the same or different sides of the substrate. For example, an electrode may be on a first side and its respective contact may be on a second side, e.g., a trace connecting the electrode and the contact may traverse through the substrate.

As noted above, analyte sensors may include an analyte-responsive enzyme to provide a sensing component or sensing layer. Some analytes, such as oxygen, can be directly electrooxidized or electroreduced on a sensor, and more specifically at least on a working electrode of a sensor. Other analytes, such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte. Catalysts may also be used for those analytes, such as oxygen, that can be directly electrooxidized or electroreduced on the working electrode. For these analytes, each working electrode includes a sensing layer (see for example sensing layer 408 of FIG. 5B) proximate to or on a surface of a working electrode. In many embodiments, a sensing layer is formed near or on only a small portion of at least a working electrode.

The sensing layer includes one or more components designed to facilitate the electrochemical oxidation or reduction of the analyte. The sensing layer may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode, an electron transfer agent to transfer electrons between the analyte and the working electrode (or other component), or both.

A variety of different sensing layer configurations may be used. In certain embodiments, the sensing layer is deposited on the conductive material of a working electrode. The sensing layer may extend beyond the conductive material of the working electrode. In some cases, the sensing layer may also extend over other electrodes, e.g., over the counter electrode and/or reference electrode (or counter/reference is provided).

A sensing layer that is in direct contact with the working electrode may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, and/or a catalyst to facilitate a reaction of the analyte. For example, a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, such as glucose oxidase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electrooxidation of the glucose, lactate, or oxygen, respectively.

In other embodiments the sensing layer is not deposited directly on the working electrode. Instead, the sensing layer 64 may be spaced apart from the working electrode, and separated from the working electrode, e.g., by a separation layer. A separation layer may include one or more membranes or films or a physical distance. In addition to separating the working electrode from the sensing layer the separation layer may also act as a mass transport limiting layer and/or an interferent eliminating layer and/or a biocompatible layer.

In certain embodiments which include more than one working electrode, one or more of the working electrodes may not have a corresponding sensing layer, or may have a sensing layer which does not contain one or more components (e.g., an electron transfer agent and/or catalyst) needed to electrolyze the analyte. Thus, the signal at this working electrode may correspond to background signal which may be removed from the analyte signal obtained from one or more other working electrodes that are associated with fully-functional sensing layers by, for example, subtracting the signal.

In certain embodiments, the sensing layer includes one or more electron transfer agents. Electron transfer agents that may be employed are electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE). The electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Examples of organometallic redox species are metallocenes such as ferrocene. Examples of inorganic redox species are hexacyanoferrate (III), ruthenium hexamine etc.

In certain embodiments, electron transfer agents have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed. For example, electron transfer agents include, but are not limited to, a redox species, e.g., bound to a polymer which can in turn be disposed on or near the working electrode. The bond between the redox species and the polymer may be covalent, coordinative, or ionic. Although any organic, organometallic or inorganic redox species may be bound to a polymer and used as an electron transfer agent, in certain embodiments the redox species is a transition metal compound or complex, e.g., osmium, ruthenium, iron, and cobalt compounds or complexes. It will be recognized that many redox species described for use with a polymeric component may also be used, without a polymeric component.

One type of polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition. An example of this type of mediator is poly(vinylferrocene). Another type of electron transfer agent contains an ionically-bound redox species. This type of mediator may include a charged polymer coupled to an oppositely charged redox species. Examples of this type of mediator include a negatively charged polymer coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation. Another example of an ionically-bound mediator is a positively charged polymer such as quaternized poly(4-vinyl pyridine) or poly(1-vinyl imidazole) coupled to a negatively charged redox species such as ferricyanide or ferrocyanide. In other embodiments, electron transfer agents include a redox species coordinatively bound to a polymer. For example, the mediator may be formed by coordination of an osmium or cobalt 2,2′-bipyridyl complex to poly(l-vinyl imidazole) or poly(4-vinyl pyridine).

Suitable electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, 1-methyl, 2-pyridyl biimidazole, or derivatives thereof. The electron transfer agents may also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof. One example of an electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same. Some derivatives of 2,2′-bipyridine for complexation with the osmium cation include, but are not limited to, 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, such as 4,4′-dimethoxy-2,2′-bipyridine. Derivatives of 1,10-phenanthroline for complexation with the osmium cation include, but are not limited to, 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline. Polymers for complexation with the osmium cation include, but are not limited to, polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”). Suitable copolymer substituents of poly(1-vinyl imidazole) include acrylonitrile, acrylamide, and substituted or quaternized N-vinyl imidazole, e.g., electron transfer agents with osmium complexed to a polymer or copolymer of poly(1-vinyl imidazole).

Embodiments may employ electron transfer agents having a redox potential ranging from about −200 mV to about +200 mV versus the standard calomel electrode (SCE). The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase, flavine adenine dinucleotide (FAD), or nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.

The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone (PQQ), dependent glucose dehydrogenase or oligosaccharide dehydrogenase, flavine adenine dinucleotide (FAD) dependent glucose dehydrogenase, nicotinamide adenine dinucleotide (NAD) dependent glucose dehydrogenase), may be used when the analyte of interest is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte of interest is lactate. Laccase may be used when the analyte of interest is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.

In certain embodiments, a catalyst may be attached to a polymer, cross linking the catalyst with another electron transfer agent (which, as described above, may be polymeric. A second catalyst may also be used in certain embodiments. This second catalyst may be used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst may operate with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode. Alternatively, a second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents.

Certain embodiments include a Wired Enzyme™ sensing layer (Abbott Diabetes Care) that works at a gentle oxidizing potential, e.g., a potential of about +40 mV. This sensing layer uses an osmium (Os)-based mediator designed for low potential operation and is stably anchored in a polymeric layer. Accordingly, in certain embodiments the sensing element is a redox active component that includes (1) Osmium—based mediator molecules attached by stable (bidente) ligands anchored to a polymeric backbone, and (2) glucose oxidase enzyme molecules. These two constituents are crosslinked together.

A mass transport limiting layer (not shown), e.g., an analyte flux modulating layer, may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes. The mass transport limiting layers are useful in limiting the flux of an analyte to a working electrode in an electrochemical sensor so that the sensor is linearly responsive over a large range of analyte concentrations and is easily calibrated. Mass transport limiting layers may include polymers and may be biocompatible. A mass transport limiting layer may provide many functions, e.g., biocompatibility and/or interferent-eliminating, etc.

In certain embodiments, a mass transport limiting layer is a membrane composed of crosslinked polymers containing heterocyclic nitrogen groups, such as polymers of polyvinylpyridine and polyvinylimidazole. Embodiments also include membranes that are made of a polyurethane, or polyether urethane, or chemically related material, or membranes that are made of silicone, and the like.

A membrane may be formed by crosslinking in situ a polymer, modified with a zwitterionic moiety, a non-pyridine copolymer component, and optionally another moiety that is either hydrophilic or hydrophobic, and/or has other desirable properties, in an alcohol-buffer solution. The modified polymer may be made from a precursor polymer containing heterocyclic nitrogen groups. For example, a precursor polymer may be polyvinylpyridine or polyvinylimidazole. Optionally, hydrophilic or hydrophobic modifiers may be used to “fine-tune” the permeability of the resulting membrane to an analyte of interest. Optional hydrophilic modifiers, such as poly(ethylene glycol), hydroxyl or polyhydroxyl modifiers, may be used to enhance the biocompatibility of the polymer or the resulting membrane.

A membrane may be formed in situ by applying an alcohol-buffer solution of a crosslinker and a modified polymer over an enzyme-containing sensing layer and allowing the solution to cure for about one to two days or other appropriate time period. The crosslinker-polymer solution may be applied to the sensing layer by placing a droplet or droplets of the solution on the sensor, by dipping the sensor into the solution, or the like. Generally, the thickness of the membrane is controlled by the concentration of the solution, by the number of droplets of the solution applied, by the number of times the sensor is dipped in the solution, or by any combination of these factors. A membrane applied in this manner may have any combination of the following functions: (1) mass transport limitation, i.e., reduction of the flux of analyte that can reach the sensing layer, (2) biocompatibility enhancement, or (3) interferent reduction.

The electrochemical sensors may employ any suitable measurement technique. For example, may detect current or may employ potentiometry. Technique may include, but are not limited to, amperometry, coulometry, and voltammetry. In some embodiments, sensing systems may be optical, colorimetric, and the like.

In certain embodiments, the sensing system detects hydrogen peroxide to infer glucose levels. For example, a hydrogen peroxide-detecting sensor may be constructed in which a sensing layer includes enzyme such as glucose oxides, glucose dehydrogenase, or the like, and is positioned proximate to the working electrode. The sending layer may be covered by a membrane that is selectively permeable to glucose. Once the glucose passes through the membrane, it is oxidized by the enzyme and reduced glucose oxidase can then be oxidized by reacting with molecular oxygen to produce hydrogen peroxide.

Certain embodiments include a hydrogen peroxide-detecting sensor constructed from a sensing layer prepared by crosslinking two components together, for example: (1) a redox compound such as a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials of about +200 mV vs. SCE, and (2) periodate oxidized horseradish peroxidase (HRP). Such a sensor functions in a reductive mode; the working electrode is controlled at a potential negative to that of the Os complex, resulting in mediated reduction of hydrogen peroxide through the HRP catalyst.

In another example, a potentiometric sensor can be constructed as follows. A glucose-sensing layer is constructed by crosslinking together (1) a redox polymer containing pendent Os polypyridyl complexes with oxidation potentials from about −200 mV to +200 mV vs. SCE, and (2) glucose oxidase. This sensor can then be used in a potentiometric mode, by exposing the sensor to a glucose containing solution, under conditions of zero current flow, and allowing the ratio of reduced/oxidized Os to reach an equilibrium value. The reduced/oxidized Os ratio varies in a reproducible way with the glucose concentration, and will cause the electrode's potential to vary in a similar way.

A sensor may also include an active agent such as an anticlotting and/or antiglycolytic agent(s) disposed on at least a portion a sensor that is positioned in a user. An anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor. Examples of useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents. Embodiments may include an antiglycolytic agent or precursor thereof. Examples of antiglycolytic agents are glyceraldehyde, fluoride ion, and mannose.

Sensors may be configured to require no system calibration or no user calibration. For example, a sensor may be factory calibrated and need not require further calibrating. In certain embodiments, calibration may be required, but may be done without user intervention, i.e., may be automatic. In those embodiments in which calibration by the user is required, the calibration may be according to a predetermined schedule or may be dynamic, i.e., the time for which may be determined by the system on a real-time basis according to various factors, such as, but not limited to, glucose concentration and/or temperature and/or rate of change of glucose, etc.

Calibration may be accomplished using an in vitro test strip (or other reference), e.g., a small sample test strip such as a test strip that requires less than about 1 microliter of sample (for example FreeStyle® blood glucose monitoring test strips from Abbott Diabetes Care). For example, test strips that require less than about 1 nanoliter of sample may be used. In certain embodiments, a sensor may be calibrated using only one sample of body fluid per calibration event. For example, a user need only lance a body part one time to obtain sample for a calibration event (e.g., for a test strip), or may lance more than one time within a short period of time if an insufficient volume of sample is firstly obtained. Embodiments include obtaining and using multiple samples of body fluid for a given calibration event, where glucose values of each sample are substantially similar. Data obtained from a given calibration event may be used independently to calibrate or combined with data obtained from previous calibration events, e.g., averaged including weighted averaged, etc., to calibrate. In certain embodiments, a system need only be calibrated once by a user, where recalibration of the system is not required.

Analyte systems may include an optional alarm system that, e.g., based on information from a processor, warns the patient of a potentially detrimental condition of the analyte. For example, if glucose is the analyte, an alarm system may warn a user of conditions such as hypoglycemia and/or hyperglycemia and/or impending hypoglycemia, and/or impending hyperglycemia. An alarm system may be triggered when analyte levels approach, reach or exceed a threshold value. An alarm system may also, or alternatively, be activated when the rate of change, or acceleration of the rate of change, in analyte level increase or decrease, approaches, reaches or exceeds a threshold rate or acceleration. A system may also include system alarms that notify a user of system information such as battery condition, calibration, sensor dislodgment, sensor malfunction, etc. Alarms may be, for example, auditory and/or visual. Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated.

Referring back to the figures, FIG. 6 illustrates steps for setting, determining or programming an alarm parameter based on glycemic excursion events in one embodiment of the present disclosure. The alarm parameter may be based on, but not limited to, a determined rate of occurrence of a glycemic excursion event (610) such as hypoglycemia or hyperglycemia, a determined frequency of alarm activation based on the glycemic excursion event (620), and/or a determined glucose level associated with the alarm activation (630).

In one aspect, the rate of occurrence of a glycemic excursion event (610) may be determined by analyzing glycemic related data for a predetermined time period, as illustrated in the flow chart of FIG. 7. Referring to FIG. 7, in one embodiment, the rate of occurrence of a glycemic excursion event is determined by monitoring a glucose level of a patient for a predetermined time period (710). During this predetermined time period, the occurrence or the frequency of the occurrence of the glucose level of the patient crossing or transcending a predetermined threshold is detected (720). The predetermined threshold, in one aspect, may be based on one or more threshold levels or parameters associated with one or more conditions, such as, for example, but not limited to, hypoglycemic condition, hyperglycemic condition, impending hyperglycemic or impending hypoglycemic conditions, a rate of change of the glucose or analyte level exceeding a set or programmed rate, or a rate of acceleration or deceleration of the glucose or analyte level fluctuation. For example, the predetermined threshold for mild hypoglycemia may be associated with a blood glucose level of approximately 70 mg/dL and the threshold for moderate hypoglycemia may be associated with a blood glucose level of approximately 60 mg/dL. Referring back to FIG. 7, the detection of the glucose level transcending or crossing the predetermined threshold may be stored in a memory or a suitable storage device such as random access memory (RAM), electrically programmable random access memory (EPROM), Flash memory and the like, and the stored information may be used to determine the rate of occurrence of the glycemic event during the predetermined time period (730).

Referring back to FIG. 6, the frequency of an alarm activation associated with the glycemic excursion event (620) is determined, as well as the glucose level associated with the alarm activation (630), which, in one aspect, is determined based on analyte sensor data received from a transcutaneous analyte sensor, such as a glucose sensor. Once the rate of occurrence of the glycemic excursion event, and the frequency of alarm activation and associated glucose level are determined, an alarm parameter may be set or programmed (or programmable) based on the determined information (640). In other aspects, information, such as the rate of change of the glucose level associated with the glycemic excursion event or the associated alarm activation or trigger event, may be determined and used to, in part, base or determine the setting/establishing of the alarm parameter. Moreover, once the alarm parameter is set or established, the alarm parameter may be used to program a notification function or routine associated with the analyte monitoring systems.

As described above, in accordance with aspects of the present disclosure, alarm or notification routines or functions may be programmed, programmable or provided to a user or a patient in conjunction with the use of an analyte monitoring system including an analyte monitoring device such as, for example, a continuous glucose sensor that provides real time monitoring of glucose levels of the patient or the user. For example, in one aspect, the frequency of the occurrence of a notification or alarm associated with a particular condition (such as, for example, a hypoglycemic condition) may be detected. The detected occurrence of such notification may be provided to an analyte monitoring system (or retrieved from the storage device or memory of such monitoring systems) and processed for further characterization, personalization or programming to improve glycemic control resulting in health treatment or therapy management.

In one aspect, programming or configuring an analyte monitoring system or other physiological condition monitoring device or system to provide notification function and/or alarm features may include monitoring and/or evaluating analyte level information obtained from a transcutaneously positioned analyte sensor, detecting conditions associated with the notification or alarm such as, for example, but not limited to, hypoglycemia, or hyperglycemia, obtaining an in vitro blood glucose measurement when the notification or alarm is output or asserted, and/or determining the frequency of such notification or alarms asserted or output to the user or the patient. In certain aspects, the in vitro blood glucose measurement results may be used to confirm the blood glucose level, for example, by comparing the analyte level associated with the asserted or output alarm notification detected and analyzed from the analyte sensor to the in vitro blood glucose measurements. In certain embodiments, the monitored analyte level information from the transcutaneously positioned in vivo analyte sensor may be used solely to determine whether the alarm or notification is triggered and not subsequently comparing the analyte level with the results of a contemporaneous in vitro blood glucose measurement. In a further aspect, the frequency of the alarm or notification assertion (which is related to or triggered by the monitored analyte level transcending or crossing a predetermined threshold level or rate of change of such monitored analyte level) may be used as a parameter or factor in determining, modifying or adjusting the alarm parameters.

In certain aspects, the detection of the alarm condition or the underlying physiological condition associated with the programmed notification includes the detection of such conditions within approximately 30 minutes of the occurrence of such conditions. For example, multiple data points received from the in vivo analyte sensor may be compared to determine (1) onset of such condition, (2) the occurrence of such condition, or (3) termination of such condition. That is, in one aspect, the alarm or notification occurrence frequency may be evaluated to determine or confirm the presence of the underlying alarm condition or the onset of the alarm condition.

Accordingly, in aspects of the present disclosure, depending upon the threshold level setting for the hypoglycemic alarm condition, the percentage of detection and/or the number of alarms/notifications triggered may vary. That is, to adjust or modify an alarm setting for an underlying condition such as the detection of or the onset of a hypoglycemic condition, the frequency of such alarm occurrence over a predetermined time period may be evaluated in conjunction with or in addition to the assessment of the monitored level rate of change information, and the in vitro blood glucose measurement reading when the alarm is asserted, among others.

In the manner described above, in accordance with aspects of the present disclosure, a user, patient or a healthcare provider may customize or adjust the notification functions or alarms programmed or programmable in analyte monitoring devices and systems such as in continuous glucose monitoring systems such that the customized or adjusted notifications or alarms are more effective in notifying, alerting and/or prompting the user or the patient to take timely corrective actions based on such notifications. For example, if a user or a patient has relatively a high tolerance level for glycemic excursions and does not wish to have the notifications or alarms associated with glycemic excursions that are relatively mild (or within a narrower range of variation), based on the frequency of the alarms or notifications that have occurred during the use of the analyte monitoring device (for example, during a five day period, or on a bi-weekly or monthly basis, or with each replacement of the analyte sensor), the user or the patient may adjust or modify the alarm or notification thresholds or parameters based on, among others, the frequency of the previously triggered notifications and/or alarms, the levels of the thresholds or set (or programmed) levels, and the like. In this manner, a more effective programming of the notification or alarm functions/features in conjunction with the monitored analyte levels may be provided to improve glycemic control and health management.

Accordingly, a method in one aspect includes determining a rate of occurrence of a glycemic excursion event, determining a frequency of an alarm activation associated with the glycemic excursion event, determining an analyte level associated with the alarm activation, and setting an alarm parameter based on one or more of the determined rate of occurrence of the glycemic excursion event, the frequency of the alarm activation associated with the glycemic excursion event or the determined analyte level.

The glycemic excursion event may include one of hypoglycemic event or hyperglycemic event.

In one aspect, determining the analyte level associated with the alarm activation may be based, at least in part, on analyte sensor data from a transcutaneous analyte sensor.

The analyte sensor may include a glucose sensor.

Also, determining a rate of occurrence of the glycemic excursion event may include monitoring a glucose level for a predetermined time period, detecting the monitored glucose level transcending a predetermined threshold glucose level, and determining the rate of occurrence based on the detected monitored glucose level transcending the predetermined threshold glucose level within the predetermined time period.

Moreover, in another aspect, the method may include determining a rate of change of the analyte level associated with the glycemic excursion event or the alarm activation, or a combination thereof.

In a further aspect, the method may include programming an alarm function based on the set alarm parameter.

An apparatus in another aspect of the present disclosure includes an interface component such as a display unit, a user interface component including input/output units, and the like, one or more processors operatively coupled to the interface component; and a memory for storing instructions which, when executed by the one or more processors, causes the one or more processors to determine a rate of occurrence of a glycemic excursion event, determine a frequency of an alarm activation associated with the glycemic excursion event, determine an analyte level associated with the alarm activation, and set an alarm parameter based on one or more of the determined rate of occurrence of the glycemic excursion event, the frequency of the alarm activation associated with the glycemic excursion event or the determined analyte level.

Another embodiment may include monitoring an analyte level for a predetermined time period, detecting the monitored analyte level crossing a predetermined threshold glucose level, determining a frequency of the detected monitored analyte level crossing the predetermined threshold analyte level within the predetermined time period, determining an analyte level associated with an alarm threshold condition, and updating an alarm parameter related to the monitored analyte level based on the determined frequency of the detected monitored analyte level crossing the predetermined threshold analyte level within the predetermined time period.

The detected analyte level crossing the predetermined threshold glucose level may be associated with an impending hypoglycemic event or an impending hyperglycemic event.

The analyte level may be a glucose level.

Moreover, an aspect may include determining a rate of change of the analyte level associated with the detected monitored analyte level crossing the predetermined threshold glucose level.

Updating the alarm parameter may include modifying an alarm triggering threshold level.

The various processes described above including the processes performed by the processor 204 (FIG. 2) in the software application execution environment in the analyte monitoring system 100 (FIG. 1) as well as any other suitable or similar processing units embodied in the processing and storage unit 307 (FIG. 3) of the primary/secondary receiver unit 104/106, and/or the data processing terminal/infusion section 105, including the processes and routines described hereinabove, may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships. The software required to carry out the inventive process, which may be stored in a memory or storage unit (or similar storage devices in the one or more components of the system 100) and executed by the processor, may be developed by a person of ordinary skill in the art and may include one or more computer program products.

Various other modifications and alterations in the structure and method of operation of the embodiments of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with certain embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims

1. One or more computer-readable non-transitory storage media comprising instructions that, when executed by one or more processors of a receiver unit for a glucose monitoring system, cause the receiver unit to perform operations comprising: setting a first alarm threshold and a first frequency of alarm activation associated with a hypoglycemic event;setting a second alarm threshold and a second frequency of alarm activation associated with a hyperglycemic event;setting a third alarm associated with an approaching hypoglycemic event, the third alarm having a third alarm threshold and a third frequency of alarm activation;periodically receiving data indicative of glucose levels detected by a glucose sensor using a wireless receiver, wherein the glucose sensor is configured to detect glucose levels in an interstitial fluid of a user, wherein a portion of the glucose sensor is configured to be transcutaneously positioned in the user such that when positioned, a data processing unit-contacting portion of the glucose sensor is configured to reside above a skin surface of the user for physical coupling to a data processing unit, and a glucose oxidase-containing portion of the glucose sensor is configured to reside below the skin surface and in contact with the interstitial fluid of the user, wherein the wireless receiver is compatible with a wireless transmitter of the data processing unit coupled with the glucose sensor and further comprising a processor, a battery, and a temperature measurement section, wherein the data indicative of the glucose levels comprises calibrated glucose levels based on a factory calibration associated with the glucose sensor;comparing the data indicative of the glucose levels to the first alarm threshold and the second alarm threshold;detecting an occurrence of the hypoglycemic event or the hyperglycemic event based on the data indicative of the glucose levels transcending the first alarm threshold or the second alarm threshold, respectively;predicting an occurrence of the approaching hypoglycemic event based on at least the data indicative of the glucose levels and the third alarm threshold; andcausing an alarm to be activated at the first frequency of alarm activation based on the detected occurrence of the hypoglycemic event, at the second frequency of alarm activation based on the detected occurrence of the hyperglycemic event, or at the third frequency of alarm activation based on the predicted occurrence of the approaching hypoglycemic event, wherein the alarm comprises a visual component displayed on a display of the receiver unit in response to the activation of the alarm and an auditory component output by the receiver unit in response to the activation of the alarm.
2. The one or more computer-readable non-transitory storage media of claim 1, wherein the data indicative of glucose levels detected by the glucose sensor are adjusted by the data processing unit using a temperature reading from the temperature measurement section.
3. The one or more computer-readable non-transitory storage media of claim 1, wherein the alarm is activated within a predetermined time period of detecting the occurrence of the hypoglycemic event or the hyperglycemic event or predicting the occurrence of the approaching hypoglycemic event.
4. The one or more computer-readable non-transitory storage media of claim 1, wherein the instructions, when executed, cause the receiver unit to perform further operations comprising detecting the occurrence of the hypoglycemic event or the hyperglycemic event based on the data indicative of the glucose levels exceeding a rate of change threshold.
5. The one or more computer-readable non-transitory storage media of claim 1, wherein the one or more processors are operably connectable to a data network to transmit at least a portion of the data indicative of the glucose levels for storage and analysis.
6. The one or more computer-readable non-transitory storage media of claim 1, wherein the visual component of the alarm comprises a prompt for the user to take corrective action based on the detected occurrence of the hypoglycemic event or the hyperglycemic event.
7. The one or more computer-readable non-transitory storage media of claim 1, wherein the instructions, when executed, cause the receiver unit to perform further operations comprising synchronizing with the wireless transmitter of the data processing unit based on identification information of the data processing unit prior to receiving the data indicative of the glucose levels detected by the glucose sensor.
8. The one or more computer-readable non-transitory storage media of claim 1, wherein the instructions, when executed, cause the receiver unit to perform further operations comprising causing a system alarm to be activated based on a detection of a system error associated with the glucose sensor or the data processing unit.
9. The one or more computer-readable non-transitory storage media of claim 1, wherein the instructions, when executed, cause the receiver unit to perform further operations comprising setting the first alarm threshold, the first frequency of alarm activation, the second alarm threshold, and the second frequency of alarm activation after the glucose sensor is transcutaneously positioned in the user.
10. The one or more computer-readable non-transitory storage media of claim 1, wherein the alarm is indicative of the occurrence of the hypoglycemic event or the hyperglycemic event occurring in real time.
11. A receiver unit for an electrochemical glucose monitoring system, comprising: a wireless receiver compatible with a wireless transmitter of a data processing unit coupled with a glucose sensor and further comprising a processor, a battery, and a temperature measurement section, wherein the glucose sensor is configured to detect glucose levels in an interstitial fluid of a user, wherein a portion of the glucose sensor is configured to be transcutaneously positioned in the user such that when positioned, a data processing unit-contacting portion of the glucose sensor is configured to reside above a skin surface of the user for coupling to the data processing unit, and a glucose oxidase-containing portion of the glucose sensor is configured to reside below the skin surface and in contact with the interstitial fluid of the user;a display;a user interface;one or more processors; anda memory coupled with the one or more processors, the memory storing instructions that, when executed by the one or more processors, cause the one or more processors to: set a first alarm threshold and a first frequency of alarm activation associated with a hypoglycemic event;set a second alarm threshold and a second frequency of alarm activation associated with a hyperglycemic event;set a third alarm associated with an approaching hypoglycemic event, the third alarm having a third alarm threshold and a third frequency of alarm activation;periodically receive data indicative of the glucose levels detected by the glucose sensor using the wireless receiver, wherein the data indicative of the glucose levels comprises calibrated glucose levels based on a factory calibration associated with the glucose sensor;compare the data indicative of the glucose levels to the first alarm threshold and the second alarm threshold;detect an occurrence of the hypoglycemic event or the hyperglycemic event based on the data indicative of the glucose levels transcending the first alarm threshold or the second alarm threshold, respectively;predict an occurrence of the approaching hypoglycemic event based on at least the data indicative of the glucose levels and the third alarm threshold; andcause an alarm to be activated at the first frequency of alarm activation based on the detected occurrence of the hypoglycemic event, at the second frequency of alarm activation based on the detected occurrence of the hyperglycemic event, or at the third frequency of alarm activation based on the predicted occurrence of the approaching hypoglycemic event, wherein the alarm comprises a visual component displayed on the display in response to the activation of the alarm and an auditory component output by the receiver unit in response to the activation of the alarm.
12. The receiver unit of claim 11, wherein the data indicative of glucose levels detected by the glucose sensor are adjusted by the data processing unit using a temperature reading from the temperature measurement section.
13. The receiver unit of claim 11, wherein the alarm is activated within a predetermined time period of detecting the occurrence of the hypoglycemic event or the hyperglycemic event or predicting the occurrence of the approaching hypoglycemic event.
14. The receiver unit of claim 11, wherein the instructions further cause the one or more processors to detect the occurrence of the hypoglycemic event or the hyperglycemic event based on the data indicative of the glucose levels exceeding a rate of change threshold.
15. The receiver unit of claim 11, wherein the one or more processors are configured to be operably connected to a data network to transmit at least a portion of the data indicative of the glucose levels for storage and analysis.
16. The receiver unit of claim 11, wherein the visual component of the alarm comprises a prompt for the user to take corrective action based on the detected occurrence of the hypoglycemic event or the hyperglycemic event.
17. The receiver unit of claim 11, wherein the instructions further cause the one or more processors to synchronize with the wireless transmitter of the data processing unit based on identification information of the data processing unit prior to the wireless receiver receiving the data indicative of the glucose levels detected by the glucose sensor.
18. The receiver unit of claim 11, wherein the instructions further cause the one or more processors to cause a system alarm to be activated based on a detection of a system error associated with the glucose sensor or the data processing unit.
19. The receiver unit of claim 11, wherein the instructions further cause the one or more processors to set the first alarm threshold, the first frequency of alarm activation, the second alarm threshold, and the second frequency of alarm activation after the glucose sensor is transcutaneously positioned in the user.
20. The receiver unit of claim 11, wherein the alarm is indicative of the occurrence of the hypoglycemic event or the hyperglycemic event occurring in real time.
21. An electrochemical glucose monitoring system, comprising: a data processing unit comprising a wireless transmitter, a memory coupled to a processor, a battery, a temperature measurement section, and a fixation element to secure the data processing unit to the user, wherein the memory stores instructions that, when executed, cause the wireless transmitter to transmit data indicative of detected glucose levels;a glucose sensor configured to detect glucose levels in an interstitial fluid of a user, wherein a portion of the glucose sensor is configured to be transcutaneously positioned in the user such that when positioned, a data processing unit-contacting portion of the glucose sensor is configured to reside above a skin surface of the user for coupling to the data processing unit, and a glucose oxidase-containing portion of the glucose sensor is configured to reside below the skin surface and in contact with the interstitial fluid of the user;anda receiver unit, comprising: a wireless receiver compatible with the wireless transmitter of the data processing unit;a display;a user interface;one or more processors; anda memory coupled with the one or more processors, the memory storing instructions that, when executed by the one or more processors, cause the one or more processors to: set a first alarm threshold and a first frequency of alarm activation associated with a hypoglycemic event;set a second alarm threshold and a second frequency of alarm activation associated with a hyperglycemic event;set a third alarm associated with an approaching hypoglycemic event, the third alarm having a third alarm threshold and a third frequency of alarm activation;periodically receive data indicative of the glucose levels detected by the glucose sensor using the wireless receiver, wherein the data indicative of the glucose levels comprises calibrated glucose levels based on a factory calibration associated with the glucose sensor;compare the data indicative of the glucose levels to the first alarm threshold and the second alarm threshold;detect an occurrence of the hypoglycemic event or the hyperglycemic event based on the data indicative of the glucose levels transcending the first alarm threshold or the second alarm threshold, respectively;predict an occurrence of the approaching hypoglycemic event based on at least the data indicative of the glucose levels and the third alarm threshold; andcause an alarm to be activated at the first frequency of alarm activation based on the detected occurrence of the hypoglycemic event or at the second frequency of alarm activation based on the detected occurrence of the hyperglycemic event, or at the third frequency of alarm activation based on the predicted occurrence of the approaching hypoglycemic event, wherein the alarm comprises a visual component displayed on the display in response to the activation of the alarm and an auditory component output by the receiver unit in response to the activation of the alarm.
22. The electrochemical glucose monitoring system of claim 21, wherein the memory of the data processing unit further stores instructions that, when executed, cause the processor to use a temperature reading from the temperature measurement section to adjust glucose readings from the glucose sensor.
23. The electrochemical glucose monitoring system of claim 21, wherein the alarm is activated within a predetermined time period of detecting the occurrence of the hypoglycemic event or the hyperglycemic event or predicting the occurrence of the approaching hypoglycemic event.
24. The electrochemical glucose monitoring system of claim 21, wherein the memory of the receiver unit further stores instructions that, when executed, cause the one or more processors to detect the occurrence of the hypoglycemic event or the hyperglycemic event based on the data indicative of the glucose levels exceeding a rate of change threshold.
25. The electrochemical glucose monitoring system of claim 21, wherein the one or more processors are configured to be operably connected to a data network to transmit at least a portion of the data indicative of the glucose levels for storage and analysis.
26. The electrochemical glucose monitoring system of claim 21, wherein the visual component of the alarm comprises a prompt for the user to take corrective action based on the detected occurrence of the hypoglycemic event or the hyperglycemic event.
27. The electrochemical glucose monitoring system of claim 21, wherein the wireless receiver receives the data indicative of the glucose levels detected by the glucose sensor after the one or more processors have synchronized with the wireless transmitter based on identification information of data processing unit.
28. The electrochemical glucose monitoring system of claim 21, wherein the memory of the receiver unit further stores instructions that, when executed, cause the one or more processors to cause a system alarm to be activated based on a detection of a system error associated with the glucose sensor or the data processing unit.
29. The electrochemical glucose monitoring system of claim 21, wherein the first alarm threshold, the first frequency of alarm activation, the second alarm threshold, and the second frequency of alarm activation are set after the glucose sensor is transcutaneously positioned in the user.
30. The electrochemical glucose monitoring system of claim 21, wherein the alarm is indicative of the occurrence of the hypoglycemic event or the hyperglycemic event occurring in real time.

RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No. 17/688,761, filed Mar. 7, 2022, which is a continuation of U.S. application Ser. No. 17/412,436, filed Aug. 26, 2021, which is a continuation of U.S. application Ser. No. 15/675,643, filed Aug. 11, 2017, which is a continuation of U.S. application Ser. No. 14/997,463 filed Jan. 15, 2016, now U.S. Pat. No. 9,730,650, which is a continuation of U.S. application Ser. No. 12/616,129 filed Nov. 10, 2009, now U.S. Pat. No. 9,326,707, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 61/113,211 filed Nov. 10, 2008, entitled “Alarm Characterization for an Adjunctive Continuous Glucose Monitoring Device”, the disclosures of each of which are incorporated herein by reference for all purposes.

US Referenced Citations (1076)

Number	Name	Date	Kind
3581062	Aston	May 1971	A
3926760	Allen et al.	Dec 1975	A
3949388	Fuller	Apr 1976	A
3960497	Acord et al.	Jun 1976	A
3978856	Michel	Sep 1976	A
4036749	Anderson	Jul 1977	A
4055175	Clemens et al.	Oct 1977	A
4129128	McFarlane	Dec 1978	A
4245634	Albisser et al.	Jan 1981	A
4327725	Cortese et al.	May 1982	A
4344438	Schultz	Aug 1982	A
4349728	Phillips et al.	Sep 1982	A
4373527	Fischell	Feb 1983	A
4392849	Petre et al.	Jul 1983	A
4425920	Bourland et al.	Jan 1984	A
4431004	Bessman et al.	Feb 1984	A
4441968	Emmer et al.	Apr 1984	A
4462048	Ross	Jul 1984	A
4478976	Goertz et al.	Oct 1984	A
4494950	Fischell	Jan 1985	A
4509531	Ward	Apr 1985	A
4527240	Kvitash	Jul 1985	A
4538616	Rogoff	Sep 1985	A
4545382	Higgins et al.	Oct 1985	A
4619793	Lee	Oct 1986	A
4671288	Gough	Jun 1987	A
4703756	Gough et al.	Nov 1987	A
4711245	Higgins et al.	Dec 1987	A
4731051	Fischell	Mar 1988	A
4731726	Allen, III	Mar 1988	A
4749985	Corsberg	Jun 1988	A
4757022	Shults et al.	Jul 1988	A
4759366	Callaghan	Jul 1988	A
4777953	Ash et al.	Oct 1988	A
4779618	Mund et al.	Oct 1988	A
4854322	Ash et al.	Aug 1989	A
4871351	Feingold	Oct 1989	A
4890620	Gough	Jan 1990	A
4925268	Iyer et al.	May 1990	A
4947845	Davis	Aug 1990	A
4953552	DeMarzo	Sep 1990	A
4986271	Wilkins	Jan 1991	A
4995402	Smith et al.	Feb 1991	A
5000180	Kuypers et al.	Mar 1991	A
5002054	Ash et al.	Mar 1991	A
5019974	Beckers	May 1991	A
5050612	Matsumura	Sep 1991	A
5055171	Peck	Oct 1991	A
5068536	Rosenthal	Nov 1991	A
5077476	Rosenthal	Dec 1991	A
5082550	Rishpon et al.	Jan 1992	A
5106365	Hernandez	Apr 1992	A
5113869	Nappholz et al.	May 1992	A
5122925	Inpyn	Jun 1992	A
5135004	Adams et al.	Aug 1992	A
5148812	Verrier et al.	Sep 1992	A
5165407	Wilson et al.	Nov 1992	A
5199428	Obel et al.	Apr 1993	A
5202261	Musho et al.	Apr 1993	A
5203326	Collins	Apr 1993	A
5204264	Kaminer et al.	Apr 1993	A
5210778	Massart	May 1993	A
5231988	Wernicke et al.	Aug 1993	A
5246867	Lakowicz et al.	Sep 1993	A
5262035	Gregg et al.	Nov 1993	A
5262305	Heller et al.	Nov 1993	A
5264104	Gregg et al.	Nov 1993	A
5264105	Gregg et al.	Nov 1993	A
5279294	Anderson et al.	Jan 1994	A
5285792	Sjoquist et al.	Feb 1994	A
5293877	O'Hara et al.	Mar 1994	A
5299571	Mastrototaro	Apr 1994	A
5313953	Yomtov et al.	May 1994	A
5320715	Berg	Jun 1994	A
5320725	Gregg et al.	Jun 1994	A
5322063	Allen et al.	Jun 1994	A
5328460	Lord et al.	Jul 1994	A
5330634	Wong	Jul 1994	A
5340722	Wolfbeis et al.	Aug 1994	A
5342789	Chick et al.	Aug 1994	A
5356786	Heller et al.	Oct 1994	A
5360404	Novacek et al.	Nov 1994	A
5365426	Siegel et al.	Nov 1994	A
5372427	Padovani et al.	Dec 1994	A
5376070	Purvis et al.	Dec 1994	A
5379238	Stark	Jan 1995	A
5384547	Lynk et al.	Jan 1995	A
5390671	Lord et al.	Feb 1995	A
5391250	Cheney, II et al.	Feb 1995	A
5400795	Murphy et al.	Mar 1995	A
5408999	Singh et al.	Apr 1995	A
5411647	Johnson et al.	May 1995	A
5425749	Adams	Jun 1995	A
5425868	Pedersen	Jun 1995	A
5431160	Wilkins	Jul 1995	A
5431921	Thombre	Jul 1995	A
5438983	Falcone	Aug 1995	A
5462645	Albery et al.	Oct 1995	A
5472317	Field et al.	Dec 1995	A
5489414	Schreiber et al.	Feb 1996	A
5497772	Schulman et al.	Mar 1996	A
5505828	Wong	Apr 1996	A
5507288	Bocker et al.	Apr 1996	A
5509410	Hill et al.	Apr 1996	A
5514718	Lewis et al.	May 1996	A
5520191	Karlsson et al.	May 1996	A
5531878	Vadgama et al.	Jul 1996	A
5543326	Heller et al.	Aug 1996	A
5552997	Massart	Sep 1996	A
5568400	Stark et al.	Oct 1996	A
5568806	Cheney, II et al.	Oct 1996	A
5569186	Lord et al.	Oct 1996	A
5582184	Erickson et al.	Dec 1996	A
5586553	Halili et al.	Dec 1996	A
5593852	Heller et al.	Jan 1997	A
5601435	Quy	Feb 1997	A
5609575	Larson et al.	Mar 1997	A
5628310	Rao et al.	May 1997	A
5628890	Carter et al.	May 1997	A
5640954	Pfeiffer et al.	Jun 1997	A
5653239	Pompei et al.	Aug 1997	A
5660163	Schulman et al.	Aug 1997	A
5665222	Heller et al.	Sep 1997	A
5711001	Bussan et al.	Jan 1998	A
5711861	Ward et al.	Jan 1998	A
5720295	Greenhut et al.	Feb 1998	A
5733259	Valcke et al.	Mar 1998	A
5735285	Albert et al.	Apr 1998	A
5741211	Renirie et al.	Apr 1998	A
5772586	Heinonen et al.	Jun 1998	A
5785660	van Lake et al.	Jul 1998	A
5791344	Schulman et al.	Aug 1998	A
5792065	Xue et al.	Aug 1998	A
5820551	Hill et al.	Oct 1998	A
5822715	Worthington et al.	Oct 1998	A
5891047	Lander et al.	Apr 1999	A
5899855	Brown	May 1999	A
5914026	Blubaugh, Jr. et al.	Jun 1999	A
5918603	Brown	Jul 1999	A
5925021	Castellano et al.	Jul 1999	A
5935224	Svancarek et al.	Aug 1999	A
5942979	Luppino	Aug 1999	A
5957854	Besson et al.	Sep 1999	A
5960797	Kramer et al.	Oct 1999	A
5961451	Reber et al.	Oct 1999	A
5964993	Blubaugh, Jr. et al.	Oct 1999	A
5965380	Heller et al.	Oct 1999	A
5971922	Arita et al.	Oct 1999	A
5973613	Reis et al.	Oct 1999	A
5995860	Sun et al.	Nov 1999	A
6001067	Shults et al.	Dec 1999	A
6016443	Ekwall et al.	Jan 2000	A
6021350	Mathson	Feb 2000	A
6024699	Surwit et al.	Feb 2000	A
6038469	Karlsson et al.	Mar 2000	A
6049727	Crothall	Apr 2000	A
6071391	Gotoh et al.	Jun 2000	A
6073031	Helstab et al.	Jun 2000	A
6083710	Heller et al.	Jul 2000	A
6088608	Schulman et al.	Jul 2000	A
6091976	Pfeiffer et al.	Jul 2000	A
6093172	Funderburk et al.	Jul 2000	A
6103033	Say et al.	Aug 2000	A
6108577	Benser	Aug 2000	A
6112116	Fischell	Aug 2000	A
6115622	Minoz	Sep 2000	A
6115628	Stadler et al.	Sep 2000	A
6117290	Say et al.	Sep 2000	A
6119028	Schulman et al.	Sep 2000	A
6120676	Heller et al.	Sep 2000	A
6121009	Heller et al.	Sep 2000	A
6121611	Lindsay et al.	Sep 2000	A
6122351	Schluet Aler, Jr. et al.	Sep 2000	A
6128526	Stadler et al.	Oct 2000	A
6134461	Say et al.	Oct 2000	A
6143164	Heller et al.	Nov 2000	A
6144837	Quy	Nov 2000	A
6159147	Lichter et al.	Dec 2000	A
6161095	Brown	Dec 2000	A
6162611	Heller et al.	Dec 2000	A
6175752	Say et al.	Jan 2001	B1
6200265	Walsh et al.	Mar 2001	B1
6212416	Ward et al.	Apr 2001	B1
6219574	Cormier et al.	Apr 2001	B1
6223283	Chaiken et al.	Apr 2001	B1
6233471	Berner et al.	May 2001	B1
6233486	Ekwall et al.	May 2001	B1
6248067	Causey, III et al.	Jun 2001	B1
6249705	Snell	Jun 2001	B1
6254586	Mann et al.	Jul 2001	B1
6256538	Ekwall	Jul 2001	B1
6264606	Ekwall et al.	Jul 2001	B1
6270455	Brown	Aug 2001	B1
6272379	Fischell et al.	Aug 2001	B1
6275717	Gross et al.	Aug 2001	B1
6283761	Joao	Sep 2001	B1
6284478	Heller et al.	Sep 2001	B1
6293925	Safabash et al.	Sep 2001	B1
6295506	Heinonen et al.	Sep 2001	B1
6299757	Feldman et al.	Oct 2001	B1
6306104	Cunningham et al.	Oct 2001	B1
6309884	Cooper et al.	Oct 2001	B1
6329161	Heller et al.	Dec 2001	B1
6338790	Feldman et al.	Jan 2002	B1
6348640	Navot et al.	Feb 2002	B1
6359444	Grimes	Mar 2002	B1
6360888	McIvor et al.	Mar 2002	B1
6361503	Starobin et al.	Mar 2002	B1
6366794	Moussy et al.	Apr 2002	B1
6377828	Chaiken et al.	Apr 2002	B1
6377852	Bornzin et al.	Apr 2002	B1
6377894	Deweese et al.	Apr 2002	B1
6379301	Worthington et al.	Apr 2002	B1
6381493	Stadler et al.	Apr 2002	B1
6387048	Schulman et al.	May 2002	B1
6405066	Essenpreis et al.	Jun 2002	B1
6413393	Van Antwerp et al.	Jul 2002	B1
6424847	Mastrototaro et al.	Jul 2002	B1
6427088	Bowman, IV et al.	Jul 2002	B1
6440068	Brown et al.	Aug 2002	B1
6461496	Feldman et al.	Oct 2002	B1
6471689	Joseph et al.	Oct 2002	B1
6478736	Mault	Nov 2002	B1
6484046	Say et al.	Nov 2002	B1
6501983	Nataraj An et al.	Dec 2002	B1
6503381	Gotoh et al.	Jan 2003	B1
6510344	Halpern	Jan 2003	B1
6514460	Fendrock	Feb 2003	B1
6514718	Heller et al.	Feb 2003	B2
6520326	McLvor et al.	Feb 2003	B2
6540891	Stewart et al.	Apr 2003	B1
6544212	Galley et al.	Apr 2003	B2
6551494	Heller et al.	Apr 2003	B1
6558320	Causey, III et al.	May 2003	B1
6558321	Burd et al.	May 2003	B1
6558351	Steil et al.	May 2003	B1
6560471	Heller et al.	May 2003	B1
6561978	Conn et al.	May 2003	B1
6562001	Lebel et al.	May 2003	B2
6564105	Starkweather et al.	May 2003	B2
6565509	Say et al.	May 2003	B1
6571128	Lebel et al.	May 2003	B2
6572542	Houben et al.	Jun 2003	B1
6574490	Abbink et al.	Jun 2003	B2
6576101	Heller et al.	Jun 2003	B1
6577899	Lebel et al.	Jun 2003	B2
6579690	Bonnecaze et al.	Jun 2003	B1
6585644	Lebel et al.	Jul 2003	B2
6591125	Buse et al.	Jul 2003	B1
6592745	Feldman et al.	Jul 2003	B1
6595919	Berner et al.	Jul 2003	B2
6600997	Deweese et al.	Jul 2003	B2
6605200	Mao et al.	Aug 2003	B1
6605201	Mao et al.	Aug 2003	B1
6607509	Bobroff et al.	Aug 2003	B2
6610012	Mault	Aug 2003	B2
6616819	Liamos et al.	Sep 2003	B1
6618934	Feldman et al.	Sep 2003	B1
6622045	Snell et al.	Sep 2003	B2
6633772	Ford et al.	Oct 2003	B2
6635014	Starkweather et al.	Oct 2003	B2
6641533	Causey, III et al.	Nov 2003	B2
6648821	Lebel et al.	Nov 2003	B2
6650471	Doi	Nov 2003	B2
6654625	Say et al.	Nov 2003	B1
6656114	Poulson et al.	Dec 2003	B1
6658396	Tang et al.	Dec 2003	B1
6659948	Lebel et al.	Dec 2003	B2
6668196	Villegas et al.	Dec 2003	B1
6675030	Ciuczak et al.	Jan 2004	B2
6676816	Mao et al.	Jan 2004	B2
6687546	Lebel et al.	Feb 2004	B2
6689056	Kilcoyne et al.	Feb 2004	B1
6694191	Starkweather et al.	Feb 2004	B2
6695860	Ward et al.	Feb 2004	B1
6698269	Baber et al.	Mar 2004	B2
6702857	Brauker et al.	Mar 2004	B2
6721582	Trepagnier et al.	Apr 2004	B2
6730200	Stewart et al.	May 2004	B1
6731985	Poore et al.	May 2004	B2
6733446	Lebel et al.	May 2004	B2
6736957	Forrow et al.	May 2004	B1
6740075	Lebel et al.	May 2004	B2
6741877	Shults et al.	May 2004	B1
6746582	Heller et al.	Jun 2004	B2
6749740	Liamos et al.	Jun 2004	B2
6758810	Lebel et al.	Jul 2004	B2
6764581	Forrow et al.	Jul 2004	B1
6770030	Schaupp et al.	Aug 2004	B1
6773671	Lewis et al.	Aug 2004	B1
6790178	Mault et al.	Sep 2004	B1
6809653	Mann et al.	Oct 2004	B1
6810290	Lebel et al.	Oct 2004	B2
6811533	Lebel et al.	Nov 2004	B2
6811534	Bowman, IV et al.	Nov 2004	B2
6813519	Lebel et al.	Nov 2004	B2
6850790	Berner et al.	Feb 2005	B2
6862465	Shults et al.	Mar 2005	B2
6865407	Kimball et al.	Mar 2005	B2
6873268	Lebel et al.	Mar 2005	B2
6881551	Heller et al.	Apr 2005	B2
6882940	Potts et al.	Apr 2005	B2
6892085	McIvor et al.	May 2005	B2
6893545	Gotoh et al.	May 2005	B2
6895263	Shin et al.	May 2005	B2
6895265	Silver	May 2005	B2
6912413	Rantala et al.	Jun 2005	B2
6923763	Kovatchev et al.	Aug 2005	B1
6931327	Goode, Jr. et al.	Aug 2005	B2
6932892	Chen et al.	Aug 2005	B2
6932894	Mao et al.	Aug 2005	B2
6936006	Sabra	Aug 2005	B2
6942518	Liamos et al.	Sep 2005	B2
6950708	Bowman, IV et al.	Sep 2005	B2
6954662	Freger et al.	Oct 2005	B2
6958705	Lebel et al.	Oct 2005	B2
6968294	Gutta et al.	Nov 2005	B2
6971274	Olin	Dec 2005	B2
6974437	Lebel et al.	Dec 2005	B2
6990366	Say et al.	Jan 2006	B2
6997907	Safabash et al.	Feb 2006	B2
6998247	Monfre et al.	Feb 2006	B2
7003336	Holker et al.	Feb 2006	B2
7003340	Say et al.	Feb 2006	B2
7003341	Say et al.	Feb 2006	B2
7010345	Hill et al.	Mar 2006	B2
7011630	Desai et al.	Mar 2006	B2
7016713	Gardner et al.	Mar 2006	B2
7016720	Kroll	Mar 2006	B2
7022072	Fox et al.	Apr 2006	B2
7022219	Mansouri et al.	Apr 2006	B2
7024245	Lebel et al.	Apr 2006	B2
7025425	Kovatchev et al.	Apr 2006	B2
7029443	Kroll	Apr 2006	B2
7029444	Shin et al.	Apr 2006	B2
7041068	Freeman et al.	May 2006	B2
7041468	Drucker et al.	May 2006	B2
7043287	Khalil et al.	May 2006	B1
7052483	Wojcik	May 2006	B2
7056302	Douglas	Jun 2006	B2
7074307	Simpson et al.	Jul 2006	B2
7076300	Kroll et al.	Jul 2006	B1
7081195	Simpson et al.	Jul 2006	B2
7092891	Maus et al.	Aug 2006	B2
7096064	Deno et al.	Aug 2006	B2
7098803	Mann et al.	Aug 2006	B2
7103412	Kroll	Sep 2006	B1
7108778	Simpson et al.	Sep 2006	B2
7110803	Shults et al.	Sep 2006	B2
7113821	Sun et al.	Sep 2006	B1
7118667	Lee	Oct 2006	B2
7123950	Mannheimer	Oct 2006	B2
7134999	Brauker et al.	Nov 2006	B2
7136689	Shults et al.	Nov 2006	B2
7142911	Boileau et al.	Nov 2006	B2
7153265	Vachon	Dec 2006	B2
7155729	Andrew et al.	Dec 2006	B1
7167818	Brown	Jan 2007	B2
7171274	Starkweather et al.	Jan 2007	B2
7183102	Monfre et al.	Feb 2007	B2
7190988	Say et al.	Mar 2007	B2
7192450	Brauker et al.	Mar 2007	B2
7198606	Boecker et al.	Apr 2007	B2
7225535	Feldman et al.	Jun 2007	B2
7226978	Tapsak et al.	Jun 2007	B2
7258673	Racchini et al.	Aug 2007	B2
7267665	Steil et al.	Sep 2007	B2
7272436	Gill et al.	Sep 2007	B2
7276029	Goode, Jr. et al.	Oct 2007	B2
7278983	Ireland et al.	Oct 2007	B2
7295867	Berner et al.	Nov 2007	B2
7297114	Gill et al.	Nov 2007	B2
7299082	Feldman et al.	Nov 2007	B2
7301463	Paterno	Nov 2007	B1
7310544	Brister et al.	Dec 2007	B2
7317938	Lorenz et al.	Jan 2008	B2
7335294	Heller et al.	Feb 2008	B2
7344500	Talbot et al.	Mar 2008	B2
7354420	Steil et al.	Apr 2008	B2
7364592	Carr-Brendel et al.	Apr 2008	B2
7366556	Brister et al.	Apr 2008	B2
7379765	Petisce et al.	May 2008	B2
7402153	Steil et al.	Jul 2008	B2
7404796	Ginsberg	Jul 2008	B2
7424318	Brister et al.	Sep 2008	B2
7460898	Brister et al.	Dec 2008	B2
7467003	Brister et al.	Dec 2008	B2
7468125	Kraft et al.	Dec 2008	B2
7471972	Rhodes et al.	Dec 2008	B2
7474992	Ariyur	Jan 2009	B2
7494465	Brister et al.	Feb 2009	B2
7497827	Brister et al.	Mar 2009	B2
7499002	Blasko et al.	Mar 2009	B2
7502644	Gill et al.	Mar 2009	B2
7519408	Rasdal et al.	Apr 2009	B2
7519478	Bartkowiak et al.	Apr 2009	B2
7523004	Bartkowiak et al.	Apr 2009	B2
7524287	Bharmi	Apr 2009	B2
7547281	Hayes et al.	Jun 2009	B2
7569030	Lebel et al.	Aug 2009	B2
7583990	Goode, Jr. et al.	Sep 2009	B2
7591801	Brauker et al.	Sep 2009	B2
7599726	Goode, Jr. et al.	Oct 2009	B2
7613491	Boock et al.	Nov 2009	B2
7615007	Shults et al.	Nov 2009	B2
7618369	Hayter et al.	Nov 2009	B2
7630748	Budiman	Dec 2009	B2
7632228	Brauker et al.	Dec 2009	B2
7635594	Holmes et al.	Dec 2009	B2
7637868	Saint et al.	Dec 2009	B2
7640048	Dobbles et al.	Dec 2009	B2
7651596	Petisce et al.	Jan 2010	B2
7654956	Brister et al.	Feb 2010	B2
7657297	Simpson et al.	Feb 2010	B2
7699775	Desai et al.	Apr 2010	B2
7699964	Feldman et al.	Apr 2010	B2
7711402	Shults et al.	May 2010	B2
7711493	Bartkowiak et al.	May 2010	B2
7713574	Brister et al.	May 2010	B2
7715893	Kamath et al.	May 2010	B2
7736310	Taub et al.	Jun 2010	B2
7751864	Buck, Jr.	Jul 2010	B2
7766829	Sloan et al.	Aug 2010	B2
7771352	Shults et al.	Aug 2010	B2
7774145	Bruaker et al.	Aug 2010	B2
7778680	Goode, Jr. et al.	Aug 2010	B2
7826981	Goode, Jr. et al.	Nov 2010	B2
7857760	Brister et al.	Dec 2010	B2
7866026	Wang et al.	Jan 2011	B1
7885697	Brister et al.	Feb 2011	B2
7889069	Fifolt et al.	Feb 2011	B2
7899511	Shults et al.	Mar 2011	B2
7905833	Brister et al.	Mar 2011	B2
7914450	Goode, Jr. et al.	Mar 2011	B2
7938797	Estes	May 2011	B2
7946984	Brister et al.	May 2011	B2
7974672	Shults et al.	Jul 2011	B2
8060173	Goode, Jr. et al.	Nov 2011	B2
8116837	Huang	Feb 2012	B2
8140312	Hayter et al.	Mar 2012	B2
8160669	Brauker et al.	Apr 2012	B2
8160900	Taub et al.	Apr 2012	B2
8170803	Kamath et al.	May 2012	B2
8211016	Budiman	Jul 2012	B2
8216137	Budiman	Jul 2012	B2
8216138	McGarraugh et al.	Jul 2012	B1
8239166	Hayter et al.	Aug 2012	B2
8255026	Al-Ali	Aug 2012	B1
8282549	Brauker et al.	Oct 2012	B2
8376945	Hayter et al.	Feb 2013	B2
8444560	Hayter et al.	May 2013	B2
8457703	Al-Ali	Jun 2013	B2
8484005	Hayter et al.	Jul 2013	B2
8532935	Budiman	Sep 2013	B2
8543354	Luo et al.	Sep 2013	B2
8571808	Hayter	Oct 2013	B2
8612163	Hayter et al.	Dec 2013	B2
8657746	Roy	Feb 2014	B2
8682615	Hayter et al.	Mar 2014	B2
9000914	Baker et al.	Apr 2015	B2
9060719	Hayter et al.	Jun 2015	B2
9113828	Budiman	Aug 2015	B2
9119528	Cobelli et al.	Sep 2015	B2
9398872	Hayter et al.	Jul 2016	B2
9408566	Hayter et al.	Aug 2016	B2
9483608	Hayter et al.	Nov 2016	B2
9558325	Hayter et al.	Jan 2017	B2
9730650	McGarraugh	Aug 2017	B2
9801541	Mensinger et al.	Oct 2017	B2
9980140	Spencer et al.	May 2018	B1
10375222	Mandapaka et al.	Aug 2019	B2
10702215	Hampapuram et al.	Jul 2020	B2
10855788	Arabo et al.	Dec 2020	B2
11213204	Mensinger et al.	Jan 2022	B2
11272890	McGarraugh	Mar 2022	B2
11991175	Rolfe et al.	May 2024	B2
20010041831	Starkweather et al.	Nov 2001	A1
20020016534	Trepagnier et al.	Feb 2002	A1
20020019022	Dunn et al.	Feb 2002	A1
20020032531	Mansky et al.	Mar 2002	A1
20020042090	Heller et al.	Apr 2002	A1
20020057993	Maisey et al.	May 2002	A1
20020065454	Lebel et al.	May 2002	A1
20020068860	Clark	Jun 2002	A1
20020103499	Perez et al.	Aug 2002	A1
20020106709	Potts et al.	Aug 2002	A1
20020120186	Keimel	Aug 2002	A1
20020128594	Das et al.	Sep 2002	A1
20020143266	Bock	Oct 2002	A1
20020143372	Snell et al.	Oct 2002	A1
20020161288	Shin et al.	Oct 2002	A1
20020169635	Shillingburg	Nov 2002	A1
20020193679	Malave et al.	Dec 2002	A1
20030004403	Drinan et al.	Jan 2003	A1
20030023317	Brauker et al.	Jan 2003	A1
20030023461	Quintanilla et al.	Jan 2003	A1
20030032867	Crothall et al.	Feb 2003	A1
20030032874	Rhodes et al.	Feb 2003	A1
20030042137	Mao et al.	Mar 2003	A1
20030050546	Desai et al.	Mar 2003	A1
20030054428	Monfre et al.	Mar 2003	A1
20030065308	Lebel et al.	Apr 2003	A1
20030088166	Say et al.	May 2003	A1
20030100821	Heller et al.	May 2003	A1
20030125612	Fox et al.	Jul 2003	A1
20030130616	Steil et al.	Jul 2003	A1
20030134347	Heller et al.	Jul 2003	A1
20030168338	Gao et al.	Sep 2003	A1
20030176933	Lebel et al.	Sep 2003	A1
20030187338	Say et al.	Oct 2003	A1
20030191377	Robinson et al.	Oct 2003	A1
20030199744	Buse et al.	Oct 2003	A1
20030199790	Boecker et al.	Oct 2003	A1
20030208113	Mault et al.	Nov 2003	A1
20030211617	Jones	Nov 2003	A1
20030212317	Kovatchev et al.	Nov 2003	A1
20030212379	Bylund et al.	Nov 2003	A1
20030216630	Jersey-Willuhn et al.	Nov 2003	A1
20030217966	Tapsak et al.	Nov 2003	A1
20030235817	Bartkowiak et al.	Dec 2003	A1
20040010186	Kimball et al.	Jan 2004	A1
20040010207	Flaherty et al.	Jan 2004	A1
20040011671	Shults et al.	Jan 2004	A1
20040024553	Monfre et al.	Feb 2004	A1
20040039298	Abreu	Feb 2004	A1
20040040840	Mao et al.	Mar 2004	A1
20040045879	Shults et al.	Mar 2004	A1
20040054263	Moerman et al.	Mar 2004	A1
20040064068	DeNuzzio et al.	Apr 2004	A1
20040077962	Kroll	Apr 2004	A1
20040078065	Kroll	Apr 2004	A1
20040093167	Braig et al.	May 2004	A1
20040099529	Mao et al.	May 2004	A1
20040106858	Say et al.	Jun 2004	A1
20040122353	Shahmirian et al.	Jun 2004	A1
20040133164	Funderburk et al.	Jul 2004	A1
20040135684	Steinthal et al.	Jul 2004	A1
20040138588	Saikley et al.	Jul 2004	A1
20040138716	Kon et al.	Jul 2004	A1
20040142403	Hetzel et al.	Jul 2004	A1
20040146909	Duong et al.	Jul 2004	A1
20040152622	Keith et al.	Aug 2004	A1
20040162678	Hetzel et al.	Aug 2004	A1
20040167801	Say et al.	Aug 2004	A1
20040171921	Say et al.	Sep 2004	A1
20040172307	Gruber	Sep 2004	A1
20040176672	Silver et al.	Sep 2004	A1
20040186362	Brauker et al.	Sep 2004	A1
20040186365	Jin et al.	Sep 2004	A1
20040193025	Steil et al.	Sep 2004	A1
20040193090	Lebel et al.	Sep 2004	A1
20040197846	Hockersmith et al.	Oct 2004	A1
20040199059	Brauker et al.	Oct 2004	A1
20040204687	Mogensen et al.	Oct 2004	A1
20040208780	Faries, Jr. et al.	Oct 2004	A1
20040225338	Lebel et al.	Nov 2004	A1
20040236200	Say et al.	Nov 2004	A1
20040249253	Racchini et al.	Dec 2004	A1
20040249420	Olson et al.	Dec 2004	A1
20040254433	Bandis et al.	Dec 2004	A1
20040254434	Goodnow et al.	Dec 2004	A1
20040260478	Schwamm	Dec 2004	A1
20040263354	Mann et al.	Dec 2004	A1
20040267300	Mace	Dec 2004	A1
20050003470	Nelson et al.	Jan 2005	A1
20050004439	Shin et al.	Jan 2005	A1
20050004494	Perez et al.	Jan 2005	A1
20050010087	Banet et al.	Jan 2005	A1
20050010269	Lebel et al.	Jan 2005	A1
20050016276	Guan et al.	Jan 2005	A1
20050027177	Shin et al.	Feb 2005	A1
20050027180	Goode et al.	Feb 2005	A1
20050027181	Goode et al.	Feb 2005	A1
20050027462	Goode et al.	Feb 2005	A1
20050027463	Goode et al.	Feb 2005	A1
20050031689	Shults et al.	Feb 2005	A1
20050038332	Saidara et al.	Feb 2005	A1
20050043598	Goode, Jr. et al.	Feb 2005	A1
20050049179	Davidson et al.	Mar 2005	A1
20050049473	Desai et al.	Mar 2005	A1
20050070774	Addison et al.	Mar 2005	A1
20050090607	Tapsak et al.	Apr 2005	A1
20050096511	Fox et al.	May 2005	A1
20050096512	Fox et al.	May 2005	A1
20050112169	Brauker et al.	May 2005	A1
20050113653	Fox et al.	May 2005	A1
20050114068	Chey et al.	May 2005	A1
20050115832	Simpson et al.	Jun 2005	A1
20050121322	Say et al.	Jun 2005	A1
20050131346	Douglas	Jun 2005	A1
20050143635	Kamath et al.	Jun 2005	A1
20050148890	Hastings	Jul 2005	A1
20050154271	Rasdal et al.	Jul 2005	A1
20050176136	Burd et al.	Aug 2005	A1
20050177398	Watanabe et al.	Aug 2005	A1
20050182306	Sloan	Aug 2005	A1
20050187720	Goode, Jr. et al.	Aug 2005	A1
20050192494	Ginsberg	Sep 2005	A1
20050192557	Brauker et al.	Sep 2005	A1
20050195930	Spital et al.	Sep 2005	A1
20050196821	Monfre et al.	Sep 2005	A1
20050199494	Say et al.	Sep 2005	A1
20050203360	Brauker et al.	Sep 2005	A1
20050209515	Hockersmith et al.	Sep 2005	A1
20050214892	Kovatchev et al.	Sep 2005	A1
20050239154	Feldman et al.	Oct 2005	A1
20050239156	Drucker et al.	Oct 2005	A1
20050241957	Mao et al.	Nov 2005	A1
20050245795	Goode, Jr. et al.	Nov 2005	A1
20050245799	Brauker et al.	Nov 2005	A1
20050245839	Stivoric et al.	Nov 2005	A1
20050245904	Estes et al.	Nov 2005	A1
20050277164	Drucker et al.	Dec 2005	A1
20050277912	John	Dec 2005	A1
20050280521	Mizumaki	Dec 2005	A1
20050287620	Heller et al.	Dec 2005	A1
20050288725	Hettrick et al.	Dec 2005	A1
20060001538	Kraft et al.	Jan 2006	A1
20060001551	Kraft et al.	Jan 2006	A1
20060004270	Bedard et al.	Jan 2006	A1
20060010098	Goodnow et al.	Jan 2006	A1
20060011474	Schulein et al.	Jan 2006	A1
20060015020	Neale et al.	Jan 2006	A1
20060015024	Brister et al.	Jan 2006	A1
20060016700	Brister et al.	Jan 2006	A1
20060017923	Ruchti et al.	Jan 2006	A1
20060019327	Brister et al.	Jan 2006	A1
20060020186	Brister et al.	Jan 2006	A1
20060020187	Brister et al.	Jan 2006	A1
20060020188	Kamath et al.	Jan 2006	A1
20060020189	Brister et al.	Jan 2006	A1
20060020190	Kamath et al.	Jan 2006	A1
20060020191	Brister et al.	Jan 2006	A1
20060020192	Brister et al.	Jan 2006	A1
20060025662	Buse et al.	Feb 2006	A1
20060025663	Talbot et al.	Feb 2006	A1
20060029177	Cranford, Jr. et al.	Feb 2006	A1
20060031094	Cohen et al.	Feb 2006	A1
20060036139	Brister et al.	Feb 2006	A1
20060036140	Brister et al.	Feb 2006	A1
20060036141	Kamath et al.	Feb 2006	A1
20060036142	Brister et al.	Feb 2006	A1
20060036143	Brister et al.	Feb 2006	A1
20060036144	Brister et al.	Feb 2006	A1
20060036145	Brister et al.	Feb 2006	A1
20060091006	Wang et al.	May 2006	A1
20060142651	Brister et al.	Jun 2006	A1
20060155180	Brister et al.	Jul 2006	A1
20060166629	Reggiardo	Jul 2006	A1
20060167365	Bharmi	Jul 2006	A1
20060167517	Gill et al.	Jul 2006	A1
20060167518	Gill et al.	Jul 2006	A1
20060167519	Gill et al.	Jul 2006	A1
20060173260	Gaoni et al.	Aug 2006	A1
20060173406	Hayes et al.	Aug 2006	A1
20060173444	Choy et al.	Aug 2006	A1
20060183984	Dobbles et al.	Aug 2006	A1
20060183985	Brister et al.	Aug 2006	A1
20060189851	Tvig et al.	Aug 2006	A1
20060189863	Peyser et al.	Aug 2006	A1
20060193375	Lee	Aug 2006	A1
20060222566	Brauker et al.	Oct 2006	A1
20060224109	Steil et al.	Oct 2006	A1
20060224141	Rush et al.	Oct 2006	A1
20060226985	Goodnow et al.	Oct 2006	A1
20060229512	Petisce et al.	Oct 2006	A1
20060247508	Fennell	Nov 2006	A1
20060247685	Bharmi	Nov 2006	A1
20060247985	Liamos et al.	Nov 2006	A1
20060258929	Goode et al.	Nov 2006	A1
20060264785	Dring et al.	Nov 2006	A1
20060272652	Stocker et al.	Dec 2006	A1
20060276771	Galley et al.	Dec 2006	A1
20060281985	Ward et al.	Dec 2006	A1
20070016381	Kamath et al.	Jan 2007	A1
20070027381	Stafford	Feb 2007	A1
20070032706	Kamath et al.	Feb 2007	A1
20070033074	Nitzan et al.	Feb 2007	A1
20070056858	Chen et al.	Mar 2007	A1
20070060803	Liljeryd et al.	Mar 2007	A1
20070060814	Stafford	Mar 2007	A1
20070066873	Kamath et al.	Mar 2007	A1
20070068807	Feldman et al.	Mar 2007	A1
20070071681	Gadkar et al.	Mar 2007	A1
20070073129	Shah et al.	Mar 2007	A1
20070078320	Stafford	Apr 2007	A1
20070078321	Mazza et al.	Apr 2007	A1
20070078322	Stafford	Apr 2007	A1
20070078323	Reggiardo et al.	Apr 2007	A1
20070095661	Wang et al.	May 2007	A1
20070106135	Sloan et al.	May 2007	A1
20070107973	Jiang et al.	May 2007	A1
20070108048	Wang et al.	May 2007	A1
20070118405	Campbell et al.	May 2007	A1
20070124002	Estes et al.	May 2007	A1
20070129621	Kellogg et al.	Jun 2007	A1
20070149875	Ouyang et al.	Jun 2007	A1
20070156033	Causey, III et al.	Jul 2007	A1
20070163880	Woo et al.	Jul 2007	A1
20070168224	Letzt et al.	Jul 2007	A1
20070173706	Neinast et al.	Jul 2007	A1
20070173709	Petisce et al.	Jul 2007	A1
20070173710	Petisce et al.	Jul 2007	A1
20070173761	Kanderian et al.	Jul 2007	A1
20070179349	Hoyme et al.	Aug 2007	A1
20070179352	Randlov et al.	Aug 2007	A1
20070179434	Weinert et al.	Aug 2007	A1
20070191701	Feldman et al.	Aug 2007	A1
20070199818	Petyt et al.	Aug 2007	A1
20070202562	Curry et al.	Aug 2007	A1
20070203407	Hoss et al.	Aug 2007	A1
20070203966	Brauker et al.	Aug 2007	A1
20070208244	Brauker et al.	Sep 2007	A1
20070213657	Jennewine et al.	Sep 2007	A1
20070227911	Wang et al.	Oct 2007	A1
20070232877	He	Oct 2007	A1
20070232878	Kovatchev et al.	Oct 2007	A1
20070232880	Siddiqui et al.	Oct 2007	A1
20070233013	Schoenberg et al.	Oct 2007	A1
20070235331	Simpson et al.	Oct 2007	A1
20070249922	Peyser et al.	Oct 2007	A1
20070255321	Gerber et al.	Nov 2007	A1
20070282299	Hellwig	Dec 2007	A1
20070294360	Ebling et al.	Dec 2007	A1
20070299617	Willis	Dec 2007	A1
20080004515	Jennewine et al.	Jan 2008	A1
20080004601	Jennewine et al.	Jan 2008	A1
20080009692	Stafford	Jan 2008	A1
20080017522	Heller et al.	Jan 2008	A1
20080021666	Goode, Jr. et al.	Jan 2008	A1
20080029391	Mao et al.	Feb 2008	A1
20080033254	Kamath et al.	Feb 2008	A1
20080039702	Hayter et al.	Feb 2008	A1
20080045824	Tapsak et al.	Feb 2008	A1
20080058625	McGarraugh et al.	Mar 2008	A1
20080064937	McGarraugh et al.	Mar 2008	A1
20080066305	Wang et al.	Mar 2008	A1
20080071156	Brister et al.	Mar 2008	A1
20080071157	McGarraugh et al.	Mar 2008	A1
20080071158	McGarraugh et al.	Mar 2008	A1
20080081977	Hayter et al.	Apr 2008	A1
20080083617	Simpson et al.	Apr 2008	A1
20080086042	Brister et al.	Apr 2008	A1
20080086044	Brister et al.	Apr 2008	A1
20080086273	Shults et al.	Apr 2008	A1
20080097246	Stafford	Apr 2008	A1
20080097289	Steil et al.	Apr 2008	A1
20080102441	Chen et al.	May 2008	A1
20080103447	Reggiardo et al.	May 2008	A1
20080108942	Brister et al.	May 2008	A1
20080119703	Brister et al.	May 2008	A1
20080119708	Budiman	May 2008	A1
20080119710	Reggiardo et al.	May 2008	A1
20080139910	Mastrototaro et al.	Jun 2008	A1
20080148873	Wang	Jun 2008	A1
20080154099	Aspel et al.	Jun 2008	A1
20080154513	Kovatchev et al.	Jun 2008	A1
20080161666	Feldman et al.	Jul 2008	A1
20080167543	Say et al.	Jul 2008	A1
20080172205	Breton et al.	Jul 2008	A1
20080177149	Weinert et al.	Jul 2008	A1
20080177165	Blomquist et al.	Jul 2008	A1
20080183060	Steil et al.	Jul 2008	A1
20080183061	Goode et al.	Jul 2008	A1
20080183399	Goode et al.	Jul 2008	A1
20080188731	Brister et al.	Aug 2008	A1
20080188796	Steil et al.	Aug 2008	A1
20080189051	Goode et al.	Aug 2008	A1
20080194934	Ray et al.	Aug 2008	A1
20080194935	Brister et al.	Aug 2008	A1
20080194936	Goode et al.	Aug 2008	A1
20080194937	Goode et al.	Aug 2008	A1
20080194938	Brister et al.	Aug 2008	A1
20080195232	Carr-Brendel et al.	Aug 2008	A1
20080195967	Goode et al.	Aug 2008	A1
20080197024	Simpson et al.	Aug 2008	A1
20080200788	Brister et al.	Aug 2008	A1
20080200789	Brister et al.	Aug 2008	A1
20080200791	Simpson et al.	Aug 2008	A1
20080201325	Doniger et al.	Aug 2008	A1
20080208025	Shults et al.	Aug 2008	A1
20080208113	Damiano et al.	Aug 2008	A1
20080214910	Buck	Sep 2008	A1
20080214915	Brister et al.	Sep 2008	A1
20080214918	Brister et al.	Sep 2008	A1
20080228051	Shults et al.	Sep 2008	A1
20080228054	Shults et al.	Sep 2008	A1
20080234943	Ray et al.	Sep 2008	A1
20080234992	Ray et al.	Sep 2008	A1
20080242961	Brister et al.	Oct 2008	A1
20080242963	Essenpreis et al.	Oct 2008	A1
20080255434	Hayter et al.	Oct 2008	A1
20080255437	Hayter	Oct 2008	A1
20080255808	Hayter	Oct 2008	A1
20080256048	Hayter	Oct 2008	A1
20080262469	Brister et al.	Oct 2008	A1
20080267823	Wang et al.	Oct 2008	A1
20080275313	Brister et al.	Nov 2008	A1
20080278333	Fennell et al.	Nov 2008	A1
20080287761	Hayter	Nov 2008	A1
20080287762	Hayter	Nov 2008	A1
20080287763	Hayter	Nov 2008	A1
20080287764	Rasdal et al.	Nov 2008	A1
20080287765	Rasdal et al.	Nov 2008	A1
20080287766	Rasdal et al.	Nov 2008	A1
20080288180	Hayter	Nov 2008	A1
20080288204	Hayter et al.	Nov 2008	A1
20080296155	Shults et al.	Dec 2008	A1
20080300572	Rankers et al.	Dec 2008	A1
20080306368	Goode et al.	Dec 2008	A1
20080306434	Dobbles et al.	Dec 2008	A1
20080306435	Kamath et al.	Dec 2008	A1
20080306444	Brister et al.	Dec 2008	A1
20080312841	Hayter	Dec 2008	A1
20080312842	Hayter	Dec 2008	A1
20080312844	Hayter et al.	Dec 2008	A1
20080312845	Hayter et al.	Dec 2008	A1
20080314395	Kovatchev et al.	Dec 2008	A1
20080319279	Ramsay et al.	Dec 2008	A1
20090005665	Hayter et al.	Jan 2009	A1
20090005666	Shin et al.	Jan 2009	A1
20090006034	Hayter et al.	Jan 2009	A1
20090006061	Thukral et al.	Jan 2009	A1
20090006133	Weinert et al.	Jan 2009	A1
20090012376	Agus	Jan 2009	A1
20090012379	Goode et al.	Jan 2009	A1
20090018424	Kamath et al.	Jan 2009	A1
20090018425	Ouyang et al.	Jan 2009	A1
20090030293	Cooper et al.	Jan 2009	A1
20090030294	Petisce et al.	Jan 2009	A1
20090030641	Fjield et al.	Jan 2009	A1
20090033482	Hayter et al.	Feb 2009	A1
20090036747	Hayter et al.	Feb 2009	A1
20090036758	Brauker et al.	Feb 2009	A1
20090036760	Hayter	Feb 2009	A1
20090036763	Brauker et al.	Feb 2009	A1
20090043181	Brauker et al.	Feb 2009	A1
20090043182	Brauker et al.	Feb 2009	A1
20090043525	Brauker et al.	Feb 2009	A1
20090043541	Brauker et al.	Feb 2009	A1
20090043542	Brauker et al.	Feb 2009	A1
20090045055	Rhodes et al.	Feb 2009	A1
20090048503	Dalal et al.	Feb 2009	A1
20090054745	Jennewine et al.	Feb 2009	A1
20090054748	Feldman et al.	Feb 2009	A1
20090054753	Robinson et al.	Feb 2009	A1
20090055149	Hayter et al.	Feb 2009	A1
20090062633	Brauker et al.	Mar 2009	A1
20090062635	Brauker et al.	Mar 2009	A1
20090062767	VanAntwerp et al.	Mar 2009	A1
20090063402	Hayter	Mar 2009	A1
20090069649	Budiman	Mar 2009	A1
20090076356	Simpson et al.	Mar 2009	A1
20090076360	Brister et al.	Mar 2009	A1
20090076361	Kamath et al.	Mar 2009	A1
20090082693	Stafford	Mar 2009	A1
20090085768	Patel et al.	Apr 2009	A1
20090099436	Brister et al.	Apr 2009	A1
20090105560	Solomon	Apr 2009	A1
20090105570	Sloan et al.	Apr 2009	A1
20090105636	Hayter et al.	Apr 2009	A1
20090112478	Mueller, Jr. et al.	Apr 2009	A1
20090118589	Ueshima et al.	May 2009	A1
20090124877	Goode, Jr. et al.	May 2009	A1
20090124878	Goode et al.	May 2009	A1
20090124879	Brister et al.	May 2009	A1
20090124964	Leach et al.	May 2009	A1
20090131768	Simpson et al.	May 2009	A1
20090131769	Leach et al.	May 2009	A1
20090131776	Simpson et al.	May 2009	A1
20090131777	Simpson et al.	May 2009	A1
20090137886	Shariati et al.	May 2009	A1
20090137887	Shariati et al.	May 2009	A1
20090143659	Ying et al.	Jun 2009	A1
20090143660	Brister et al.	Jun 2009	A1
20090143725	Peyser et al.	Jun 2009	A1
20090149717	Brauer et al.	Jun 2009	A1
20090149728	Van Antwerp et al.	Jun 2009	A1
20090156919	Brister et al.	Jun 2009	A1
20090156924	Shariati et al.	Jun 2009	A1
20090163790	Brister et al.	Jun 2009	A1
20090163791	Brister et al.	Jun 2009	A1
20090163855	Shin et al.	Jun 2009	A1
20090164190	Hayter	Jun 2009	A1
20090164239	Hayter et al.	Jun 2009	A1
20090164251	Hayter	Jun 2009	A1
20090178459	Li et al.	Jul 2009	A1
20090182217	Li et al.	Jul 2009	A1
20090182517	Gandhi et al.	Jul 2009	A1
20090192366	Mensinger et al.	Jul 2009	A1
20090192380	Shariati et al.	Jul 2009	A1
20090192722	Shariati et al.	Jul 2009	A1
20090192724	Brauker et al.	Jul 2009	A1
20090192745	Kamath et al.	Jul 2009	A1
20090192751	Kamath et al.	Jul 2009	A1
20090198118	Hayter et al.	Aug 2009	A1
20090203981	Brauker et al.	Aug 2009	A1
20090204341	Brauker et al.	Aug 2009	A1
20090216103	Brister et al.	Aug 2009	A1
20090240120	Mensinger et al.	Sep 2009	A1
20090240128	Mensinger et al.	Sep 2009	A1
20090240193	Mensinger et al.	Sep 2009	A1
20090242399	Kamath et al.	Oct 2009	A1
20090242425	Kamath et al.	Oct 2009	A1
20090247855	Boock et al.	Oct 2009	A1
20090247856	Boock et al.	Oct 2009	A1
20090247857	Harper et al.	Oct 2009	A1
20090253973	Bashan et al.	Oct 2009	A1
20090275815	Bickoff et al.	Nov 2009	A1
20090281406	McGarraugh et al.	Nov 2009	A1
20090281407	Budiman	Nov 2009	A1
20090287073	Boock et al.	Nov 2009	A1
20090287074	Shults et al.	Nov 2009	A1
20090294277	Thomas et al.	Dec 2009	A1
20090299155	Yang et al.	Dec 2009	A1
20090299156	Simpson et al.	Dec 2009	A1
20090299162	Brauker et al.	Dec 2009	A1
20090299276	Brauker et al.	Dec 2009	A1
20100010324	Brauker et al.	Jan 2010	A1
20100010331	Brauker et al.	Jan 2010	A1
20100010332	Brauker et al.	Jan 2010	A1
20100014626	Fennell et al.	Jan 2010	A1
20100016687	Brauker et al.	Jan 2010	A1
20100016698	Rasdal et al.	Jan 2010	A1
20100022855	Brauker et al.	Jan 2010	A1
20100030038	Brauker et al.	Feb 2010	A1
20100030053	Goode, Jr. et al.	Feb 2010	A1
20100030484	Brauker et al.	Feb 2010	A1
20100030485	Brauker et al.	Feb 2010	A1
20100036215	Goode, Jr. et al.	Feb 2010	A1
20100036216	Goode, Jr. et al.	Feb 2010	A1
20100036222	Goode, Jr. et al.	Feb 2010	A1
20100036223	Goode, Jr. et al.	Feb 2010	A1
20100036225	Goode, Jr. et al.	Feb 2010	A1
20100041971	Goode, Jr. et al.	Feb 2010	A1
20100045425	Chivallier	Feb 2010	A1
20100045465	Brauker et al.	Feb 2010	A1
20100049024	Saint et al.	Feb 2010	A1
20100057040	Hayter	Mar 2010	A1
20100057041	Hayter	Mar 2010	A1
20100057042	Hayter	Mar 2010	A1
20100057044	Hayter	Mar 2010	A1
20100057057	Hayter et al.	Mar 2010	A1
20100063372	Potts et al.	Mar 2010	A1
20100063373	Kamath et al.	Mar 2010	A1
20100064764	Hayter et al.	Mar 2010	A1
20100076283	Simpson et al.	Mar 2010	A1
20100079402	Goode et al.	Apr 2010	A1
20100081908	Dobbles et al.	Apr 2010	A1
20100081910	Brister et al.	Apr 2010	A1
20100081953	Syeda-Mahmood et al.	Apr 2010	A1
20100087724	Brauker et al.	Apr 2010	A1
20100096259	Zhang et al.	Apr 2010	A1
20100099970	Shults et al.	Apr 2010	A1
20100099971	Shults et al.	Apr 2010	A1
20100119693	Tapsak et al.	May 2010	A1
20100121167	McGarraugh et al.	May 2010	A1
20100121169	Petisce et al.	May 2010	A1
20100141656	Krieftewirth	Jun 2010	A1
20100145172	Petisce et al.	Jun 2010	A1
20100160759	Celentano et al.	Jun 2010	A1
20100160760	Shults et al.	Jun 2010	A1
20100161269	Kamath et al.	Jun 2010	A1
20100168538	Keenan et al.	Jul 2010	A1
20100168540	Kamath et al.	Jul 2010	A1
20100168541	Kamath et al.	Jul 2010	A1
20100168542	Kamath et al.	Jul 2010	A1
20100168543	Kamath et al.	Jul 2010	A1
20100168544	Kamath et al.	Jul 2010	A1
20100168545	Kamath et al.	Jul 2010	A1
20100168546	Kamath et al.	Jul 2010	A1
20100168657	Kamath et al.	Jul 2010	A1
20100174157	Brister et al.	Jul 2010	A1
20100174158	Kamath et al.	Jul 2010	A1
20100174163	Brister et al.	Jul 2010	A1
20100174164	Brister et al.	Jul 2010	A1
20100174165	Brister et al.	Jul 2010	A1
20100174166	Brister et al.	Jul 2010	A1
20100174167	Kamath et al.	Jul 2010	A1
20100174168	Goode et al.	Jul 2010	A1
20100174266	Estes	Jul 2010	A1
20100179399	Goode et al.	Jul 2010	A1
20100179400	Brauker et al.	Jul 2010	A1
20100179401	Rasdal et al.	Jul 2010	A1
20100179402	Goode et al.	Jul 2010	A1
20100179404	Kamath et al.	Jul 2010	A1
20100179405	Goode et al.	Jul 2010	A1
20100179407	Goode et al.	Jul 2010	A1
20100179408	Kamath et al.	Jul 2010	A1
20100179409	Kamath et al.	Jul 2010	A1
20100185065	Goode et al.	Jul 2010	A1
20100185069	Brister et al.	Jul 2010	A1
20100185070	Brister et al.	Jul 2010	A1
20100185071	Simpson et al.	Jul 2010	A1
20100185072	Goode et al.	Jul 2010	A1
20100185073	Goode et al.	Jul 2010	A1
20100185074	Goode et al.	Jul 2010	A1
20100185075	Brister et al.	Jul 2010	A1
20100191082	Brister et al.	Jul 2010	A1
20100191472	Doniger et al.	Jul 2010	A1
20100198034	Thomas et al.	Aug 2010	A1
20100198035	Kamath et al.	Aug 2010	A1
20100198036	Kamath et al.	Aug 2010	A1
20100198142	Sloan et al.	Aug 2010	A1
20100198314	Wei	Aug 2010	A1
20100204557	Kiaie et al.	Aug 2010	A1
20100213057	Feldman et al.	Aug 2010	A1
20100268157	Wehba et al.	Oct 2010	A1
20100280441	Willinska et al.	Nov 2010	A1
20100312176	Lauer et al.	Dec 2010	A1
20100313105	Nekoomaram et al.	Dec 2010	A1
20100317952	Budiman et al.	Dec 2010	A1
20100324392	Yee et al.	Dec 2010	A1
20100326842	Mazza et al.	Dec 2010	A1
20110021889	Hoss et al.	Jan 2011	A1
20110024043	Boock et al.	Feb 2011	A1
20110024307	Simpson et al.	Feb 2011	A1
20110027127	Simpson et al.	Feb 2011	A1
20110027453	Boock et al.	Feb 2011	A1
20110027458	Boock et al.	Feb 2011	A1
20110028815	Simpson et al.	Feb 2011	A1
20110028816	Simpson et al.	Feb 2011	A1
20110029247	Kalathil	Feb 2011	A1
20110040163	Telson et al.	Feb 2011	A1
20110060530	Fennell	Mar 2011	A1
20110077490	Simpson et al.	Mar 2011	A1
20110077494	Doniger et al.	Mar 2011	A1
20110082484	Saravia et al.	Apr 2011	A1
20110106011	Cinar et al.	May 2011	A1
20110106126	Love et al.	May 2011	A1
20110112696	Yodfat et al.	May 2011	A1
20110131307	El Bazzal et al.	Jun 2011	A1
20110148905	Simmons et al.	Jun 2011	A1
20110173308	Gutekunst	Jul 2011	A1
20110178717	Goodnow et al.	Jul 2011	A1
20110184267	Duke et al.	Jul 2011	A1
20110190603	Stafford	Aug 2011	A1
20110191044	Stafford	Aug 2011	A1
20110193704	Harper et al.	Aug 2011	A1
20110202495	Gawlick	Aug 2011	A1
20110208027	Wagner et al.	Aug 2011	A1
20110208155	Palerm et al.	Aug 2011	A1
20110213225	Bernstein	Sep 2011	A1
20110257495	Hoss et al.	Oct 2011	A1
20110257895	Brauker et al.	Oct 2011	A1
20110263958	Brauker et al.	Oct 2011	A1
20110288574	Curry et al.	Nov 2011	A1
20110319729	Donnay et al.	Dec 2011	A1
20110320130	Valdes et al.	Dec 2011	A1
20120010642	Lee et al.	Jan 2012	A1
20120078071	Bohm et al.	Mar 2012	A1
20120108934	Valdes et al.	May 2012	A1
20120165626	Irina et al.	Jun 2012	A1
20120165640	Galley et al.	Jun 2012	A1
20120173200	Breton et al.	Jul 2012	A1
20120185416	Baras et al.	Jul 2012	A1
20120209099	Ljuhs et al.	Aug 2012	A1
20120215462	Goode et al.	Aug 2012	A1
20120277565	Budiman	Nov 2012	A1
20120313785	Hanson et al.	Dec 2012	A1
20130035575	Mayou et al.	Feb 2013	A1
20130109944	Sparacino et al.	May 2013	A1
20130231541	Hayter et al.	Sep 2013	A1
20140012511	Mensinger et al.	Jan 2014	A1
20140121488	Budiman	May 2014	A1
20140221966	Buckingham et al.	Aug 2014	A1
20140266785	Miller et al.	Sep 2014	A1
20140313052	Yarger et al.	Oct 2014	A1
20140379273	Petisce et al.	Dec 2014	A1
20150123810	Hernandez-Rosas et al.	May 2015	A1
20150205947	Berman et al.	Jul 2015	A1
20150207796	Love et al.	Jul 2015	A1
20150216456	Budiman	Aug 2015	A1
20150241407	Ou et al.	Aug 2015	A1
20150366510	Budiman	Dec 2015	A1
20160022221	Ou et al.	Jan 2016	A1

Foreign Referenced Citations (79)

Number	Date	Country
4401400	Jul 1995	DE
0098592	Jan 1984	EP
0127958	Dec 1984	EP
0320109	Jun 1989	EP
0353328	Feb 1990	EP
0390390	Oct 1990	EP
0396788	Nov 1990	EP
0472411	Feb 1992	EP
0286118	Jan 1995	EP
0867146	Sep 1998	EP
1048264	Nov 2000	EP
1419731	May 2004	EP
0939602	Sep 2004	EP
1850909	Apr 2010	EP
1677668	Jul 2010	EP
3 210 137	Mar 2021	EP
2914159	Apr 2021	EP
3 831 282	Mar 2022	EP
2939158	Mar 2022	EP
4 070 727	Oct 2022	EP
4 070 727	Jul 2023	EP
3988471	Jul 2023	EP
2004-358261	Dec 2004	JP
WO-1996025089	Aug 1996	WO
WO-1996035370	Nov 1996	WO
WO-1997015227	May 1997	WO
WO-1998035053	Aug 1998	WO
WO-1999056613	Nov 1999	WO
WO-2000049940	Aug 2000	WO
WO-2000059370	Oct 2000	WO
WO 0078213	Dec 2000	WO
WO-2000074753	Dec 2000	WO
WO-2000078992	Dec 2000	WO
WO-2001052935	Jul 2001	WO
WO-2001054753	Aug 2001	WO
WO-2002016905	Feb 2002	WO
WO-2002058537	Aug 2002	WO
WO-2003076893	Sep 2003	WO
WO-2003082091	Oct 2003	WO
WO-2003085372	Oct 2003	WO
WO 2004006982	Jan 2004	WO
WO-2004060455	Jul 2004	WO
WO-2004061420	Jul 2004	WO
WO-2005010756	Feb 2005	WO
WO-2005041766	May 2005	WO
WO 2005065538	Jul 2005	WO
WO-2005065542	Jul 2005	WO
WO-2005089103	Sep 2005	WO
WO 2005119524	Dec 2005	WO
WO 2005121785	Dec 2005	WO
WO-2006024671	Mar 2006	WO
WO 2006079114	Jul 2006	WO
WO 2006079867	Aug 2006	WO
WO-2006081336	Aug 2006	WO
WO-2006085087	Aug 2006	WO
WO-2006086423	Aug 2006	WO
WO 2006118947	Nov 2006	WO
WO 2007016399	Feb 2007	WO
WO 2007027788	Mar 2007	WO
WO 2007041069	Apr 2007	WO
WO 2007041070	Apr 2007	WO
WO 2007041248	Apr 2007	WO
WO 2007056638	May 2007	WO
WO-2007097754	Aug 2007	WO
WO 2007101223	Sep 2007	WO
WO 2007120363	Oct 2007	WO
WO 2007126444	Nov 2007	WO
WO 2007053832	Dec 2007	WO
WO 2007143225	Dec 2007	WO
WO-2008001366	Jan 2008	WO
WO-2008086541	Jul 2008	WO
WO 2009136372	Nov 2009	WO
WO 2011026053	Mar 2011	WO
WO 2012154286	Nov 2012	WO
WO 2014070456	May 2014	WO
WO 2014105631	Jul 2014	WO
WO 2015069797	May 2015	WO
WO 2015069797	May 2015	WO
WO 2016092448	Jun 2016	WO

Non-Patent Literature Citations (409)

Entry
U.S. Appl. No. 12/616,129 (U.S. Pat. No. 9,326,707), filed Nov. 10, 2009 (May 3, 2016).
U.S. Appl. No. 14/997,463 (U.S. Pat. No. 9,730,650), filed Jan. 15, 2016 (Aug. 15, 2017).
U.S. Appl. No. 15/675,643 (2017/0360381), filed Aug. 11, 2017 (Dec. 21, 2017).
U.S. Appl. No. 17/412,436 (U.S. Pat. No. 11,272,890), filed Aug. 26, 2021 (Mar. 15, 2022).
U.S. Appl. No. 17/688,761 (2022/0192610), filed Mar. 7, 2022 (Jun. 23, 2022).
U.S. Appl. No. 17/688,761, Mar. 30, 2023 Notice of Allowance.
U.S. Appl. No. 17/688,761, Mar. 22, 2023 Request for Continued Examination (RCE).
U.S. Appl. No. 17/688,761, Feb. 8, 2023 Notice of Allowance.
U.S. Appl. No. 17/688,761, Jan. 18, 2023 Request for Continued Examination (RCE).
U.S. Appl. No. 17/688,761, Oct. 19, 2022 Notice of Allowance.
U.S. Appl. No. 17/688,761, Oct. 6, 2022 Response After Final Action.
U.S. Appl. No. 17/688,761, Sep. 12, 2022 Final Office Action.
U.S. Appl. No. 17/688,761, Aug. 26, 2022 Response to Non-Final Office Action.
U.S. Appl. No. 17/688,761, May 26, 2022 Non-Final Office Action.
U.S. Appl. No. 17/412,436, Jan. 31, 2022 Issue Fee Payment.
U.S. Appl. No. 17/412,436, Jan. 24, 2022 Notice of Allowance.
U.S. Appl. No. 17/412,436, Jan. 12, 2022 Terminal Disclaimer Filed.
U.S. Appl. No. 15/675,643, Sep. 23, 2021 Abandonment.
U.S. Appl. No. 15/675,643, Jun. 1, 2021 Advisory Action.
U.S. Appl. No. 15/675,643, Apr. 27, 2021 Response to Final Office Action.
U.S. Appl. No. 15/675,643, Mar. 4, 2021 Final Office Action.
U.S. Appl. No. 15/675,643, Oct. 23, 2020 Response to Non-Final Office Action.
U.S. Appl. No. 15/675,643, Jul. 23, 2020 Non-Final Office Action.
U.S. Appl. No. 15/675,643, Jun. 26, 2020 Response to Restriction Requirement.
U.S. Appl. No. 15/675,643, Jan. 3, 2020 Restriction Requirement.
U.S. Appl. No. 12/616,129, Jan. 27, 2016 Issue Fee Payment.
U.S. Appl. No. 12/616,129, Dec. 16, 2015 Notice of Allowance.
U.S. Appl. No. 12/616,129, Nov. 23, 2015 Response After Final Action.
U.S. Appl. No. 12/616,129, Nov. 19, 2015 Applicant Initiated Interview Summary.
U.S. Appl. No. 12/616,129, Oct. 8, 2015 Final Office Action.
U.S. Appl. No. 12/616,129, Oct. 8, 2015 Applicant Initiated Interview Summary.
U.S. Appl. No. 12/616,129, Jun. 16, 2015 Final Office Action.
U.S. Appl. No. 12/616,129, Feb. 20, 2015 Response to Non-Final Office Action.
U.S. Appl. No. 12/616,129, Nov. 20, 2014 Non-Final Office Action.
U.S. Appl. No. 12/616,129, Jun. 20, 2014 Amendment and Request for Continued Examination (RCE).
U.S. Appl. No. 12/616,129, Dec. 20, 2013 Final Office Action.
U.S. Appl. No. 12/616,129, Jul. 26, 2013 Applicant Initiated Interview Summary.
U.S. Appl. No. 12/616,129, Jul. 1, 2013 Response to Non-Final Office Action.
U.S. Appl. No. 12/616,129, Apr. 2, 2013 Non-Final Office Action.
U.S. Appl. No. 12/616,129, Mar. 1, 2013 Response to Restriction Requirement.
U.S. Appl. No. 12/616,129, Feb. 4, 2013 Restriction Requirement.
U.S. Appl. No. 14/997,463, Jul. 6, 2017 Issue Fee Payment.
U.S. Appl. No. 14/997,463, Apr. 11, 2017 Notice of Allowance.
U.S. Appl. No. 14/997,463, Mar. 29, 2017 Response After Final Action.
U.S. Appl. No. 14/997,463, Feb. 27, 2017 Advisory Action.
U.S. Appl. No. 14/997,463, Jan. 31, 2017 Response After Final Action.
U.S. Appl. No. 14/997,463, Dec. 1, 2016 Final Office Action.
U.S. Appl. No. 14/997,463, Aug. 25, 2016 Response to Non-Final Office Action.
U.S. Appl. No. 14/997,463, Jun. 3, 2016 Non-Final Office Action.
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.
Arnold, M. A., et al., “Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors”, Journal of Diabetes Science and Technology, vol. 1, No. 4, 2007, pp. 454-462.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.
Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
Blendea, M. C., et al, “Heart Disease in Diabetic Patients”, Current Diabetes Reports, vol. 3, 2003, pp. 223-229.
Boyne, M. S., et al., “Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor”, Diabetes, vol. 52, Nov. 2003, pp. 2790-2794.
Bremer, T. M., et al., “Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 409-418.
Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/88, pp. 45-56.
Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.
Cheyne, E. H., et al., “Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers”, Diabetes Technology & Therapeutics, vol. 4, No. 5, 2002, pp. 607-613.
Choleau, C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-Point Calibration Method”, Biosensors and Bioelectronics, vol. 17, No. 8, 2002, pp. 647-654.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.
Diabetes Control and Complications Trial Research Group, “The Effect of Intensive Treatment of Diabetes on the Development and progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus,” New England J. Med. vol. 329, 1993, pp. 977-986.
Eckert, B. et al. “Hypoglycaemia Leads to an Increased QT Interval in Normal Men,” Clinical Physiology, vol. 18, No. 6, 1998, pp. 570-575.
Eren-Oruklu, M., et al., “Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models”, Diabetes Technology & Therapeutics vol. 11(4), 2009, pp. 243-253.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired EnzymeTM Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004.
Guerci, B., et al., “Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs”, Diabetes Care, vol. 26, 2003, pp. 582-589.
Harris, N.D., et al., “Can Changes in QT Interval be Used to Predict the Onset of Hypoglycemia in Type 1 Diabetes?”, Computers in Cardiology, vol. 27, 2000, pp. 375-378.
Heller, S. R., “Abnormalities of the Electrocardiogram During Hypoglycemia: The Cause of the Dead in Bed Syndrome?” International Journal of Clinical Practice, Suppl. No. 129, 2002, pp. 27-32.
Hovorka, R., et al., “Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes”, Physiological Measurement, vol. 55, Jul. 2004, pp. 905-920.
Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652.
Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jones, T. W., et al., “Mild Hypoglycemia and Impairment of Brain Stem and Cortical Evoked Potentials in Healthy Subjects,” Diabetes vol. 39, 1990, 1550-1555.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, 2002, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Kovatchev, B. P., et al., “Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors”, Diabetes Care, vol. 27, No. 8, 2004, pp. 1922-1928.
Kovatchev, B. P., et al., “Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag”, Diabetes Technology & Therapeutics, vol. 11, No. 3, 2009, pp. 139-143.
Kuure-Kinsey, M., et al., “A Dual-Rate Kalman Filter for Continuous Glucose Monitoring”, Proceedings of the 28th IEEE, EMBS Annual International Conference, New York City, 2006, pp. 63-66.
Landstedt-Hallin, L., et al., “Increased QT Dispersion During Hypoglycaemia in Patients with Type 2 Diabetes Mellitus,” Journal of Internal Medicine, vol. 246, 1999, 299-307.
Lodwig, V., et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 573-587.
Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.
Malmberg, K., “Prospective Randomised Study of Intensive Insulin Treatment on Long-Term Survival After Acute Myocardial Infarction in Patients with Diabetes Mellitus”, British Medical Journal, vol. 314, 1997, pp. 1512-1515.
Markel, A. et al, “Hypoglycaemia-Induced Ischaemic ECG Changes”, Presse Medicale, vol. 23, No. 2, 1994, pp. 78-79.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 2001, 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.
McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.
Morbiducci, U, et al., “Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation”, Clinical Science, vol. 112, 2007, pp. 257-263.
Mougiakakou, et al., “A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients”, Proceedings of the 2005 IEEE, 2005, pp. 298-301.
Okin, P. M., et al, “Electrocardiographic Repolarization Complexity and Abnormality Predict All-Cause and Cardiovascular Mortality in Diabetes,” Diabetes, vol. 53, 2004, pp. 434-440.
Panteleon, A. E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration”, Diabetes Technology & Therapeutics, vol. 5, No. 3, 2003, pp. 401-410.
Parker, R., et al., “Robust H∞ Glucose Control in Diabetes Using a Physiological Model”, AIChE Journal, vol. 46, No. 12, 2000, pp. 2537-2549.
Peterson, K., et al., “Regulation of Serum Potassium During Insulin-Induced Hypoglycemia,” Diabetes, vol. 31, 1982, pp. 615-617.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/88, pp. 335-346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, the American Physiological Society, 1995, E155-E161.
Rana, B. S., et al., “Relation of QT Interval Dispersion to the Number of Different Cardiac Abnormalities in Diabetes Mellitus”, The American Journal of Cardiology, vol. 90, 2002, pp. 483-487.
Robinson, R. T. C. E., et al. “Changes in Cardiac Repolarization During Clinical Episodes of Nocturnal Hypoglycaemia in Adults with Type 1 Diabetes,” Diabetologia, vol. 47, 2004, pp. 312-315.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.
Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.
Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.
Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131.
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.
Steil, G. M., et al., “Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor”, Diabetes Technology & Therapeutics, vol. 5, No. 1, 2003, pp. 27-31.
Steil, G.M., et al., “Closed-Loop Insulin Delivery—the Path of Physiological Glucose Control”, Advanced Drug Delivery Reviews, vol. 56, 2004, pp. 125-144.
Steinhaus, B. M., et al., “The Information Content of the Cardiac Electrogram at the Stimulus Site,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 12, No. 2, 1990, 0607-0609.
Sternberg, R., et al., “Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.
Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.
U.S. Appl. No. 12/616,129, Notice of Allowance dated Dec. 16, 2015.
U.S. Appl. No. 12/616,129, Office Action dated Apr. 2, 2013.
U.S. Appl. No. 12/616,129, Office Action dated Dec. 20, 2013.
U.S. Appl. No. 12/616,129, Office Action dated Jun. 16, 2015.
U.S. Appl. No. 12/616,129, Office Action dated Nov. 20, 2014.
U.S. Appl. No. 12/616,129, Office Action dated Oct. 8, 2015.
U.S. Appl. No. 14/997,463, Advisory Action dated Feb. 27, 2017.
U.S. Appl. No. 14/997,463, Notice of Allowanced dated Apr. 11, 2017.
U.S. Appl. No. 14/997,463, Office Action dated Dec. 1, 2016.
U.S. Appl. No. 14/997,463, Office Action dated Jun. 3, 2016.
Abbott's Continuous Blood Glucose Monitor Approval Soon, 3 pages (2006).
About Dexcom—Continuous Glucose Monitoring Company, 12 pages (2021).
About the Congressional Record, Congress.gov, Library of Congress, 3 pages (2022).
Amendment No. 2 to the OUS Commercialization Agreement, 12 pages (2011).
ANZHSN National Horizon Scanning Unit Horizon Scanning Report, GlucoWatch{circle around (8)}G2 Biographer for the non-invasive monitoring of glucose levels, AHTA, 46 pages (2004).
Bindra, D. S., et al., Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring, Analytical Chemistry, vol. 63, No. 17, pp. 1692-1696 (1991).
Bode, B., et al., Alarms Based on Real-Time Sensor Glucose Values Alert Patients to Hypo- and Hyperglycemia: the Guardian Continuous Monitoring System, Diabetes Technology & Therapeutics, vol. 6, No. 2, pp. 105-113 (2004).
Brown, A., et al., test drive—Dexcom's G4 Platinum CGM , diatribe Learn, 4 pages (2012).
Buckingham, B., et al., Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension, Diabetes Care, vol. 33, No. 5, pp. 1013-1017 (2010).
Burton, H.D., Urging FDA to Act Promptly to Approve Artificial Pancreas Technologies, Congressional Record (Bound Edition), vol. 157, Part 13,3 pages (2011).
Choudhary, P., et al., Insulin Pump Therapy with Automated Insulin Suspension in Response to Hypoglycemia, Reduction in nocturnal hypoglycemia in those at greatest risk, Diabetes Care, vol. 34, pp. 2023-2025 (2011).
Claims, Specification and Drawings for System and Methods for Providing Sensitive and Specific Alarms, 103 pages.
Clarke, W., et al., Statistical Tools to Analyze Continuous Glucose Monitor Data, Diabetes Technology & Therapeutics, vol. 11, Supplement 1, pp. S-45-S-54 (2009).
Clemens, A.H., et al., Development of the Biostator Glucose Clamp Algorithm, Artificial Systems for Insulin Delivery, edited by Brunetti, P., et al., Serono Symposia Publications from Raven Press, vol. 6, 13 pages (1983).
Close, K., Test Driving Dexcom's Short-Term Sensor (STS): A Look at Continuous Glucose Monitoring, diaTribe Learn, 2 pages (2006).
Continuous Glucose Monitoring (CGM ) / Real-Time Flash Glucose Scanning (FGS) Training for Healthcare Professionals and Patients, Association of Children's Diabetes Clinicians, 50 pages (2017).
Cunningham, D .D., et al., in Vivo Glucose Sensing, Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley, 466 pages (2010).
Declaration of Dr. David Rodbard in Support of Petition for Inter Partes Review of Claims 1-5, 12, 19 and 23 of U.S. Pat. No. 10,702,215, Inter Partes Review No. IPR2022-00909 (2022).
Declaration of Duncan Hall (2021) including DexCom™ STS™ Continuous Glucose Monitoring System User's Guide (2006), 64 pages.
Dexcom Request for Confidentiality for FCC ID: PH29433, 1 page (2010).
DexCom™ STS™ Continuous Glucose Monitoring System User's Guide, 57 pages (2006).
Diabetes Close Up—Conferences—#2—Diabetes Technology, 8 pages (2003).
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System, ClinicalTrials.gov, 4 pages (2010).
Exhibit CP-10, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Standards of Medical Care in Diabetes-2009, American Diabetes Association, Diabetes Care, vol. 32, Supplement 1, pp. S13-S61 (2009).
Exhibit CP-2, Expert Report of Dr. Cesar C . Palerm, Sep. 20, 2022: Sparacino, et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, IEEE Transactions on Biomedical Engineering, vol. 54, No. 5, pp. 931-937 (2007).
Exhibit CP-3, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: In Vivo Glucose Sensing, Chemical Analysis, a Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley (2010).
Exhibit CP-4, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Animas® Vibe™, the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval (2011).
Exhibit CP-6, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Bailey, et al., Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring Results from a 12-Week Observational Study, Diabetes Technology & Therapeutics, vol. 9, No. 3, pp. 203-210 (2007).
Exhibit CP-7, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Improvement in Glycemic Excusions With a Transcutaneous, Real-Time Continuous Glucose Sensor, Diabetes Care, vol. 29, No. 1, pp. 44-50 (2006).
Exhibit CP-8, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values, Diabetes Care, vol. 29, No. 12, pp. 2644-2649 (2006).
Exhibit CP-9, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Welcome to Your FreeStyle Libre System, In-Service Guide, Abbott (2017).
Exhibit No. 10, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 Diabetes Research Roadmap, Identifying the strengths and weaknesses, gaps and opportunities of UK type 1 diabetes research; clearing a path to the cure, JDRF Improving Lives. Curing Type 1 Diabetes. Join us in fi nding the cure for type 1 diabetes (2013).
Exhibit No. 11, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, The New England Journal of Medicine, vol. 329, No. 14 (1993).
Exhibit No. 12, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Modern Standards and Service Models, Diabetes, National Service Framework for Diabetes: Standards, Department of Health (2000).
Exhibit No. 13, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Training in flexible, intensive, insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ, vol. 325 (2002).
Exhibit No. 14, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, Clinical Guideline 15, NIHS, National Institute for Clinical Excellence (2004).
Exhibit No. 15, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011).
Exhibit No. 16, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Pickup, et al., Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data, BMJ (2011).
Exhibit No. 17, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Diabetes (type 1), NIHR (2011).
Exhibit No. 18, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Aleppo, et al., REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring with and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes, Diabetes Care, vol. 40, pp. 538-545 (2017).
Exhibit No. 19, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol. 40, pp. 155-157 (2017).
Exhibit No. 2, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Committee for Proprietary Medicinal Products (CPI\4P), Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus, EMEA, the European Agency for the Evaluation of Medicinal Products (2002).
Exhibit No. 20, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Continuous Glucose Sensors: Continuing Questions about Clinical Accuracy, J Diabetes Sci Technol vol. 1, Issue 5, pp. 669-675 (2007).
Exhibit No. 21, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: DeVries, Glucose Sensing Issues for the Artificial Pancreas, Journal of Diabetes Science and Technology, vol. 2, Issue 4, pp. 732-734 (2008).
Exhibit No. 22, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Innovation Milestones, et al.
Exhibit No. 23, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® System Gold™ Continuous Glucose Monitoring Overview, Medtronic MiniMed (2004).
Exhibit No. 24, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: GlucoWatch G2, Automatic Glucose Biographer and Auto Sensors (2002).
Exhibit No. 25, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed (2006).
Exhibit No. 26, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022 CGMS® iPro™ Continuous Glucose Recorder, User Guide, Medtronic MiniMed (2007).
Exhibit No. 27, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator, Continuous Glucose Monitoring System, User Guide, Abbott (2008, 2010).
Exhibit No. 28, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator II, Continuous Glucose Monitoring System, User's Manual, Abbott (2011-2013).
Exhibit No. 29, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Dexcom G4, Continuous Glucose Monitoring System, User's Guide (2013).
Exhibit No. 3, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Defining and Reporting Hypoglycemia in Diabetes, Diabetes Care, vol. 28, No. 5, pp. 1245-1249 (2005).
Exhibit No. 30, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for US 2007/208244A1.
Exhibit No. 31, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for EP625.
Exhibit No. 32, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Puhr, et al., Real-World Hypoglycemia Avoidance with a Predictive Low Glucose Alert Does Not Depend on Frequent Screen Views, Journal of Diabetes Science and Technology, vol. 14(1), pp. 83-86 (2020).
Exhibit No. 33, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Rilstone, et al., The impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for people with type 1 diabetes: Pace study (2022).
Exhibit No. 34, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 2, Flash Glucose Monitoring System, User's Manual, Abbott (2019-2021).
Exhibit No. 35, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 3, Continuous Glucose Monitoring System, User's Manual, Abbott (2022).
Exhibit No. 37, to the Second Expert Report of Professor Nick Oliver, Oct. 21, 2022: Oliver, et al., Review Article, Glucose sensors, a review of current and emerging technology, Diabetic Medicine, vol. 26, pp. 197-210 (2009).
Exhibit No. 4, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Amiel, et al., Review Article, Hypoglycaemia in Type 2 diabetes, Diabetic Medicine, vol. 25, pp. 245-254 (2008).
Exhibit No. 5, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Swinnen, et al., Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia, Diabetologia, vol. 52, pp. 38-41 (2009).
Exhibit No. 6, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Frier, Defining hypoglycaemia: what level has clinical relevance?, Diabetologia, vol. 52, pp. 31-34 (2009).
Exhibit No. 7, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Cryer, Preventing hypoglycaemia: what is the appropriate glucose alert value?, Diabetologia, vol. 52, pp. 35-37 (2009).
Exhibit No. 8, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022 Oxford Textbook of Endocrinology and Diabetes (2011).
Exhibit No. 9, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, European Medicines Agency, Science Medicines Health (2012).
Facchinetti, A, et al., A New Index to Optimally Design and Compare Continuous Glucose Monitoring Glucose Prediction Algorithms, Diabetes Technology & Therapeutics, vol. 13, No. 2, pp. 111-119 (2011).
FDA PMA Approvals, 3 pages (2022).
FDA Premarket Approval (PMA) for Biostator GCIIS, PMA No. P790028, 3 pages, Notice Date: Feb. 20, 1981.
FDA Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor, 6 pages, Notice Date: Apr. 1, 2008.
Feature Analysis, 1 page.
Federal Register, vol. 76, No. 120, pp. 36542-36543 (2011).
Federal Register, vol. 86, No. 211, pp. 60827-60829 (2021).
Fogt, E.J., et al., Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator®), Clinical Chemistry, vol. 24, No. 8, pp. 1366-1372 (1978).
FreeStyle Navigator, Continuous Glucose Monitoring System, User Guide, Abbott, 2008, 196 pages.
FreeStyle Navigator® Continuous Glucose Monitoring System, User's Guide, Abbott, 38 pages (2008).
FreeStyle Navigator® Continuous Glucose Monitoring System, User's Guide, Abbott, 196 pages (2008).
Garg, S., et al., Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor, a randomized controlled trail, Diabetes Care, vol. 29, No. 1, pp. 44-50 (2006).
Garg, S.K., et al., Diabetes Technology & Therapeutics, vol. 13, No. 8, 15 pages (2011).
Garg, S.K., et al., Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults with Type 1 Diabetes, Diabetes Care, vol. 27, No. 3, pp. 734-738 (2004).
Glucowatch G2, Automatic Glucose Biographer and Auto Sensors, 70 pages (2002).
Glucowatch{circle around (8)}G21M Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children, Diabetes Technol Ther, 6(5), 12 pages (2004).
Gross, T .M, et al., Performance Evaluation of the MiniMed® Continuous Glucose Monitoring System During Patient Home Use, Diabetes Technology & Therapeutics, vol. 2, No. 1, pp. 49-56 (2000).
Grounds of Invalidity amended pursuant to CPR17.1(2)(a), Claim No. HP-2021-000025, 17 pages (2022).
Guerra, S., et al., A Dynamic Risk Measure from Continuous Glucose Monitoring Data, Diabetes Technology & Therapeutics, vol. 13, No. 8, pp. 843-852 (2011).
Hanlon, M. “DexCom' s 7-Day STS Continuous Glucose Monitoring System,” Health & Wellbeing, 2007, 1 page.
Hayter, P.G. et al., Performance Standards for Continuous Glucose Monitors, Diabetes Technology & Therapeutics, vol. 7, No. 5, pp. 72 1-726 (2005).
Heinemann, L., et al., Glucose Clamps with the Biostator: A Critical Reappraisal, Horm. Metab. Res., 26, pp. 579-583 (1994).
Heller, A., et al., Electrochemical Glucose Sensors and Their Applications in Diabetes Management, Chemical Reviews, vol. 108, No. 7, pp. 2482-2505 (2008).
Heller, A., et al., Electrochemistry in Diabetes Management, Accounts of Chemical Research, vol. 43, No. 7, pp. 963-973 (2010).
Heller, A., Integrated Medical Feedback Systems for Drug Delivery, AIChE Journal, vol. 51, No. 4, pp. 1054-1066 (2005).
Hermanns, N., et al., the Impact of Continuous Glucose Monitoring on Low Interstitial Glucose Values and Low Blood Glucose Values Assessed by Point-of-care Blood Glucose Meters: Results of a Crossover Trial, Journal of Diabetes Science and Technology, vol. 8(3), pp. 5 16-522 (2014).
Instructions for Use DexCom™ STS™ Sensor, 1 page (2006).
Instructions for Use DexCom™ STS™ Sensor, 51 pages (2006).
International Standard, IEC 6060 1-1-8, Medical Electrical Equipment, 166 pages (2006).
Javanmardi, C.A., et al., G4 Platinum Continuous Glucose Monitor, U .S. Pharmacist, 38(9), 8 pages (2013).
Kamath, A, et al., “Method of Evaluating the Utility of Continuous Glucose Monitor Alerts”, Journal of Diabetes Science and Technology, vol. 4, Issue 1, 2010, pp. 57-66.
Kovatchev, B.P., et al., Assessment of Risk for Severe Hypoglycemia Among Adults with IDDM, Validation of the low blood glucose index, Diabetes Care, vol. 21, No. 11, 7 pages. (1998).
Kovatchev, B.P., et al., Risk Analysis of Blood Glucose Data: A Quantitative Approach to Optimizing the Control of Insulin Dependent Diabetes, Journal of Theoretical Medicine, vol. 3, 11 Pages (2000).
Kovatchev, B.P., et al., Symmetrization of the Blood Glucose Measurement Scale and Its Applications, Diabetes Care, vol. 20, No. 11, pp. 1655-1658 (1997).
Letter from Department of Health & Human Services re. FreeStyle Navigator Continuous Glucose Monitoring System, 7 pages (2008).
Letter from Department of Health & Human Services re. MiniMed Continuous Glucose Monitoring System, 7 pages (1999).
Letter to EPO re. Divisional Application of EP Application No. 13784079.9 in the name of Dexcom, Inc., 2 pages (2020).
Ley, T., Continuous Glucose Monitoring: A Movie is Worth a Thousand Pictures, A Review of the Medtronic Guardian REAL-time system, 3 pages.
McMurry, J.F., the Artificial Pancreas Today, Henry Ford Hospital Medical Journal, vol. 31, No. 2, Article 4, 8 pages (1983).
Medtronic User Guide, Guardian® Real-Time Continuous Glucose Monitoring System, 184 pages (2006).
MiniMed® 530G System User Guide, Medtronic, 317 pages (2012).
Original Premarket Approval Application, FreeStyle Navigator Continuous Glucose Monitoring System, Section VII: Manufacturing Section, Steven Label Sensor Sheet Validation Plan, vol. 28 of31, TheraSense, Inc., 61 pages (2005).
OUS Commercialization Agreement, Exhibit 10.2, 49 pages (2009).
Palerm, C.C., et al., Hypoglycemia Detection and Prediction Using Continuous Glucose Monitoring—A Study on Hypoglycemic Clamp Data, Journal of Diabetes Science and Technology. vol. 1, Issue 5, pp. 624-629 (2007).
Premarket Approval Application Amendment, FreeStyle Navigator Continuous Glucose Monitoring System, vol. 2 of 39, Section III, Device Description, Abbott Diabetes Care, Inc., 89 pages (2006).
Press Release Details, DexCom Receives FDA Approval for STS™ Continuous Glucose Monitoring System, 3 pages (2006).
Rodbard, D., A Semilogarithmic Scale for Glucose Provides a Balanced View of Hyperglycemia and Hypoglycemia, Journal of Diabetes Science and Technology, vol. 3, Issue 6, pp. 1395-1401 (2009).
Sandham, W., et al., Blood Glucose Prediction for Diabetes Therapy Using a Recurrent Artificial Neural Network, 4 pages (1998).
Sparacino, G., et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, IEEE Transactions on Biomedical Engineering, vol. 54, No. 5, pp. 931-937 (2007).
STS® Seven Continuous Glucose Monitoring System, User's Guide, 74 pages (2007).
Summary of Safety and Effectiveness Data for Continuous Glucose Monitor, 27 pages (2008).
Summary of Safety and Effectiveness Data for DexComTM STSTM Continuous Glucose Monitoring System, 20 pages (2006).
Summary of Safety and Effectiveness Data for STS{circle around (8)}-7 Continuous Glucose Monitoring System, 14 pages (2007).
The CGM Resource Center References/Bibliography, 14 pages.
The Dexcom Seven Plus Quick Start Guide, 2 pages (2010).
The only CGM approved for kids ages 2 years and up, Children with Diabetes, Report from Diabetes Technology Meeting, 3 pages (2003).
TheraSense Files Premarket Approval Application for Freestyle Navigator(TM) Cont, 3 pages (2003).
TheraSense Navigates Continuous Glucose Monitor PMA , Prepares for Flash, The Gray Sheet, vol. 29, No. 37, 2 pages (2003).
U.S. Food & Drug Administration, Premarket Approval (PMA) for Continuous Glucose Monitoring System, PMA No. P980022, 20 pages, Notice Date: Jul. 14, 1999.
U.S. Food & Drug Administration, Premarket Approval (PMA) for Dexcom STS Continuous Monitors, PMA No. P0500 12, 8 ppages, Notice Date: May 12, 2006.
U.S. Food & Drug Administration, Premarket Approval (PMA) for Dexcom Seven Plus System, PMA No. P0500 12, 3 pages, Date Received: Aug. 20, 2009.
U.S. Food & Drug Administration, Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor, PMA No. P050020, 6 pages, Notice Date: Apr. 1, 2008.
United States Securities and Exchange Commission, Form 10-K, Dexcom, Inc., 59 pages (2005).
United States Securities and Exchange Commission, Form 10-K, Dexcom, Inc., 55 pages (2006).
United States Securities and Exchange Commission, Form 5-1, Dexcom, Inc., 309 pages (2005).
Williams, S., et al., The Guardian REAL-Time Continuous Glucose Monitoring System, U.S. Pharmacist, 32(12), 16 pages (2007).
Alva et al., “Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System with Advanced Algorithm in Pediatric and Adult Population with Diabetes,” Journal of Diabetes Science and Technology, vol. 16(1) 70-77 (2022).
Campbell et al., “Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study,” Pediatric Diabetes, 1294-1301 (2018).
Deshmuk et al., “Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit,” https://doi.org/10.2337/dc20-0738, Diabetes Care, 8 pages (2020).
Deutscher Gesundheitsbericht, Diabetes 2021, Die Bestandsaufnahme with English Abstract.
FDA, STS-7 Continuous Glucose Monitoring System, P050012/S001, May 31, 2007, 95 pages.
Haak et al., “Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes,” Diabetes Ther., 14 pages (2017).
Roussel et al., “Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The Relief Study,” American Diabetes Association, Diabetes Care, 1368-1376 (2021).
File history of U.S. Appl. No. 61/551,773, filed Oct. 26, 2011.
Harvey, et al., Clinically Relevant Hypoglycemia Prediction Metrics for Event Mitigation, Diabetes Technology & Therapeutics. Vol. 14, No. 8, pp. 719-727 (2012).
Hughes, et al., Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data, Journal of Diabetes Science and Technology, vol. 4, Issue 5, pp. 1146-1155 (2010).
Premarket Approval Letter with Summary of Safety and Effectiveness Data for the Freestyle Navigator Continuous Glucose Monitor, Mar. 12, 2008 [34 pgs.].
Schiavon, An online method for prevention of the risk of glycemic shock in diabetic patients from continuous glucose monitoring data, 117 pages (2010) with English translation of summary attached.
User Guide for the Navigator Freestyle (Mar. 2008) [38 pgs.].
Schiavon, A method online for there prevention of the risk of glycerine shock in diabetic patients from data of monitoring continuous of the glucose [with English translation], 220 pages (2010).
Townsend, et al., Getting Started with Bluetooth Low Energy, Tools and Techniques for Low-Power Networking, O'Reilly, 180 pages (2014).
Wang, et al., NYIT School of Engineering and Computing Sciences, A Feasible IMD Communication Protocol: Security without Obscurity, 1 page (2015).
Ballard, “User Interface Design Guidelines for J2ME Midp 2.0” 9 pages (2005).
U.S. Appl. No. 61/238,657, filed Aug. 31, 2009, 198 pages.
U.S. Appl. No. 61/238,657, filed Aug. 31, 2009, 60 pages.
U.S. Appl. No. 61/247,541, filed Sep. 30, 2009, 69 pages.
U.S. Appl. No. 61/297,265, filed Jan. 22, 2010, 54 pages.
Cunningham et al., Winefordner Seried Editor, “Chemical Analysis: A Seried of Monographs on Analytical Chemistry and Its Applications—In Vivo Glucose Sensing” 50 pages (2010).
Declaration of Thomas Edward Foster of Taylor Wessing LLP, Hill House, 1 Little New St. London EC4A 3TR (“Taylor Wessing”), in Relation to STS-7 User's Guide, Jan. 30, 2024, 160 pagesf.
DexCom STS-7 Approval Order, Department of Health and Human Services, FDA, May 31, 2007, 7 pages.
FDA Premarket Approval PMA Order for the STS-7, 3 pages, May 31, 2007.
File History of U.S. Pat. No. 10,375,222, issued Aug. 6, 2019, 442 pages.
Microsoft Applications for Windows Mobile 6 User Guide, 184 pages (2008).
NFC Forum, Bluetooth® Secure Simple Pairing Using NFC Application Document NFC Forum TM, NFCForum-AD-BTSSP_ 1_1, Jan. 9, 2014, 39 pages.
Omre, Bluetooth Low Energy: Wireless Connectivity for Medical Monitoring, Journal of Diabetes Science and Technology, vol. 4, Issue 2, 457-463 Mar. 2010.
Padgette et al., “Guide to Bluetooth Security, Recommendations of the National Institute of Standards and Technology,” National Institute of Standards and Technology, U.S. Department of Commerce, Special Publication 800-121 Revision 1, 48 pages, May 2007.
Specification Bluetooth System Experience More, 134 pages, Jun. 2010.
Specification Bluetooth System Wireless connections, 92 pages, Nov. 2003.
Stone et al., “User Interface Design and Evaluation,” The Open University, 13 pages (2005).
Strömmer et al., “Application of Near Field Communication for Health Monitoring in Daily Life,” Proceedings of the 28th IEEE FrC09.1 EMBS Annual International Conference New York City, USA, 3246-3249, Aug 30-Sept 3, 2006.
Wayback Machine internet archive of US FDA CDRH PMA Final Decisions Rendered, 21 pages, May 2007.
Wayback Machine internet archive of US FDA CDRH PMA for STS-7, May 31, 2007, 1 page.
Zhang et al., “Bluetooth Low Energy for Wearable Sensor-based Healthcare Systems,” 2014 Health Innovations and Point-of-Care Technologies Conference Seattle, Washington USA, 251-254, Oct. 8-10, 2014.
About the Congressional Record, Congress. Gov, 3 pages, Feb. 22, 2022.
Approved Judgment, In the High Court of Justice Business and Property Courts of England and Wales Intellectual Property List (ChD) Patents Court, Case No. HP-2021-000025 & HP-2021-000026, 137 pages Jan. 15, 2024.
Bequette, “Continuous Glucose Monitoring: Real-Time Algorithms for Calibration, Filtering, and Alarms,” Journal of Diabetes Science and Technology, vol. 4, Issue 2, 404-418, Mar. 2010.
Breen, The iPhone Pocket Guide, Sixth Edition, Peachpit Press, 96 pages (2012).
Brown et al., “test drive - Dexcom's G4 Platinum CGM,” diaTribe Learn Making Sense of Diabetes, 4 pages (2012).
Dassau et al., Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring, A safety net for the artificial pancreas, Diabetes Care, vol. 33, No. 3, 1249-1254 (2010).
Declaration of Dr. Sayfe Kiael, Ph.D., Inter Partes Review of U.S. Pat. No. 10,375,222, 100 pages (2024).
Declaration of David Rodbard, M.D., Petition for Inter Partes Review of U.S. Pat. No. 9,119,528, IPR2024-00840, 109 pages, May 1, 2024.
Declaration of Lane Desborough, Petition for Inter Partes Review of U.S. Pat. No. 11,213,204, IPR2024-00853, 150 pages, May 3, 2024.
Declaration of Sylvia D. Hall-Ellis, Ph.D., IPR2024-00840 of U.S. Pat. No. 9,119,528, Parts 1-2 (400 pages) Apr. 24, 2024.
Department of Health & Human Services, Fda, P050012/S001, STS-7 Continuous Glucose Monitoring System, 7 pages May 31, 2007.
DeSalvo et al., “Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia,” Diabetes Technology & Therapeutics, vol. 16, No. 1, 10 pages, DOI: 10.1089/dia.2013.0139 (2014).
Dexcom, Leading the Way for You & Your Patients with Continuous Glucose Monitoring, 12 pages (2010).
Facchinetti et al., “A New Index to Optimally Design and Compare Continuous Glucose Monitoring Glucose Prediction Algorithms,” Diabetes Technology & Therapeutics, vol. 13, No. 2, 111-119 (2011).
FDA, Draft Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption and Premarket Approval Applications for Low Glucose Suspend Device Systems; Availability, Federal Register / vol. 76, No. 120 / Wednesday, Jun. 22, 2011 /Notices, 2 pages.
FDA Premarket Approval (PMA), Seven Plus Continuous Glucose Monitoring System, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050012S001, 3 pages May 31, 2007.
FDA PMA Final Decisions Rendered for May 2007 The Wayback Machine https://web.archive.org/web/20070630150626/http:/www.fda.gov/cdrh/pma/pmamay07.html, 1 page, May 31, 2007.
FDA PMA Final Decisions Rendered for May 2007 - The Wayback Machine - https://web.archive.org/web/20070630150626/http:/www.fda.gov/cdrh/pma/pmamay07.html, 21 pages, Jun. 13, 2007.
FDA FreeStyle Navigator Continuous Glucose Monitoring System, P050020, 7 pages Mar. 12, 2008.
File History of U.S. Pat. No. 9,119,528 issued Sep. 1, 2015, Parts 1-8 (1,438 pages).
File History of U.S. Pat. No. 9,801,541 issued Oct. 31, 2017, 834 pages.
File History of U.S. Pat. No. 11,213,204 issued Jan. 1, 2022, 848 pages.
Freestyle Navigator Continuous Glucose Monitoring System, User's Guide, 195 pages (2008).
Glucowatch G2, Automatic Glucose Biographer and AutoSensors, 70 pages (2001).
Joint Claim Construction Chart, Abbott Diabetes Care Inc v. Dexcom, Inc., C.A. No. 23-239 (KAJ), 28 pages, Mar. 21, 2024.
Keith-Hynes et al., “The Diabetes Assistant: A Smartphone-Based System for Real-Time Control of Blood Glucose,” Electronics, 3, 609-623; doi:10.3390/electronics3040609 (2014).
Klonoff et al., “Innovations in Technology for the Treatment of Diabetes: Clinical Development of the Artificial Pancreas (an Autonomous System),” Journal of Diabetes Science and Technology, vol. 5, Issue 3, 804-826, May 2011.
Kowalski, “Can We Really Close the Loop and How Soon? Accelerating the Availability of an Artificial Pancreas: A Roadmap to Better Diabetes Outcomes,” Diabetes Technology & Therapeutics, vol. 11, Suppl 1, DOI: 10.1089/dia.2009.0031, S-113-S-119, 10 pages (2009).
Ley, “Continuous Glucose Monitoring: A Movie is Worth a Thousand Pictures A Review of the Medtronic Guardian REAL-time system,” https://nfb.org/images/nfb/publications/vod/vod_22_4/vodfal0702.htm, 3 pages (2021).
McDaniel et al., “Remote Management of Cardiac Patients, The Forefront of a New Standard,” Modern Healthcare, 6 pages, Nov. 14, 2011.
MySentry™M User Guide, Medronic Minimed, 80 pages (2010).
Padgette et al., “Guide to Bluetooth Security, Recommendations of the National Institute of Standards and Technology,” NET Special Publication 800421 Revision National Institute of Standards and Technology, U.S. Department of Commerce, 48 pages (2012).
Palerm et al., “Hypoglycemia Prediction and Detection Using Optimal Estimation,” Diabetes Technology & Therapeutics, vol. 7, No. 1, 12 pages (2005).
Pickup, “Semi-Closed-Loop Insulin Delivery Systems: Early Experience with Low-Glucose Insulin Suspend Pumps,” Diabetes Technology & Therapeutics, vol. 13, No. 7, DOI: 10.1089/dia.2011.0103, 695-698 (2011).
Place et al., “DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas Outpatient Trials,” Journal of Diabetes Science and Technology vol. 7, Issue 6, 1427-1435 (2013).
Scheduling Order, Abbott Diabetes Care Inc v. Dexcom, Inc., C.A. No. 23-239 (KAJ), 14 pages, Sep. 19, 2023.
Schiavon, “A method online For there prevention of the risk of glycerine shock in diabetic patients from data Of rmonitoring continuous of the glucose,” Thesis (with English translation) 219 pages Apr. 20, 2010.
Steil et al., “Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes,” Diabetes, vol. 55, 3344-3350 (2006).
The Diabetes Research in Children Network (DirecNet) Study Group, “GlucoWatch® G2TM Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children*,” Diabetes Technol Ther., 6(5): 559-566 (2004).
Weinstein et al., “Diabetes Care, ADA 2006: Spotlight on Continuous Glucose Monitoring,” JP Morgan, North America Equity Research, 16 pages, Jun. 11, 2006.
Weinzimer et al., “Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients with Type 1 Diabetes Using an Artificial Pancreas,” Emerging Treatments and Technologies, Diabetes Care, vol. 31, No. 5, 934-939 (2008).
Wettlaufer, “Merlin.Net Automation of External Reports Verification Process,” A Thesis Presented to The Faculty of California Polytechnic State University, San Luis Obispo, 53 pages, Jan. 2010.
Williams et al., “The Guardian REAL-Time Continuous Glucose Monitoring System,” U.S. Pharmacist The Pharmacist's Resource for Clinical Excellence, US Pharm., 32(12), 62-65 (2007).
Wilson et al., “Introduction to the Glucose Sensing Problem,” In Vivo Glucose Sensing, Edited by D. D. Cunningham and J. A. Stenken, Wiley & Sons, Inc., 27 pages, (2010).
Wright et al., “Continuous Glucose Monitoring (CGM)/Real-Time Flash Glucose Scanning (FGS) Training for Healthcare Professionals and Patients,” Association of Children's Diabetes Clinicians, 50 pages (2017).
A Dictionary of Computer Science, Seventh Edition, Oxford University Press, “authentication”, 3 pages (2016).
A Dictionary of Computing, Sixth Edition, Oxford University Press, “function”, 3 pages (2008).
Ananthi, “A Text Book of Medical Instruments,” New Age International (P) Limited, Publishers, 7 pages (2005).
Annex A2 Documents relating to the Patent Extract from the EP Register for the Patent, EP 3988471, 6 pages (2023).
Annex B1 Evidence relating to infringing products Dexcom G6 Start Here Guide, 21 pages (2023).
Annex B3 User Guide LibreLinkUp, 28 pages (2023).
Annex B4 Extract from the pricacy notice for Libre View, 7 pages (2024).
Annex C1 Evidence relating to infringing acts Materials concerning supply of Dexcom's Products in France, 10 pages (2022).
Annex D1 UPC Court of Appeal Feb. 26, 2024, 335/2023, 38 pages (2024).
Annex D38 Info Technology Digest, vol. 5 Issue 5, 32 pages (1996).
Annex D39 Best Practice for Software Asset Management, 7 pages (2023).
Annex D40 Nagpal, “Computer Fundamentals, concepts, Systems and Applications,” 5 pages (2008).
Annex D45 Cunningham, In Vivo Glucose Sensing, 9 pages (2010).
Annex E3 Excerpts from the “German Health Report Diabetes 2023” of the German Diabetes Society, 23 pages (2023) with English translation.
Annex F5 Application to amend the Patent under R30 RoP, 5 pages (2024).
Annex G2 Case law of the Boards of Appeal, I.C-4.3, 3 pages (2024).
Annex G3 European Patent Guide, 23rd ed., chapter 3 (“Patentability”), 3.4, 6 pages (2023).
Annex G5 Case Law of the Boards of Appeal, I-D, 4.2.0, 2 pages (2023).
Annex G6 UPC Court of Appeal Feb. 26, 2024 NanoString Technologies v. 10x Genomics, 38 pages (2024).
Annex G7 Decision of the Enlarged Board of the EPO, G 3/14 97 pages (2015).
Annex G8 Willem Hoyng, “The Unified Patent Court (UPC) opens its doors! Some observations”, 42 pages (2023).
Annex G10 Düsseldorf Local Division Oct. 18, 2023, UPC_CFI 177 2023 (MyStromer v Revolt Zycling), 19 pages (2023).
Annex G11 Munich Local Division Apr. 23, 2024, UPC CFI 514/2023 (Volkswagen AG, Audi AG, Texas Instruments Inc. and Texas Instruments Deutschland GmbH v. Network system Technologies LLC), 10 pages (2024).
Annex G12 Munich Local Division, Sep. 19, 2023, UPC_CFI_2/2023 (NanoString Technologies v. 10x Genomics), 107 pages (2023).
Annex G13 Regulation 2017/745 (EU), 176 pages (2017).
Annex G14 P. England, 'A Practitioner's Guide to the Unified Patent Court and Unitary Patent', Hart Publishing 2022, p. 159, 7 pages (2022).
“Biomedical Engineering Desk Reference,” Elsevier, 5 pages (2009).
Burr et al., Electronic Authentication Guideline, NIST Special Publication 800-63-2, Nist U.S. Dept. of Commerce, Aug. 2013, 123 pages.
Cunningham et al., “In Vivo Glucose Sensing,” Wiley & Sons, 111 pages (2010).
Cunningham et al., “In Vivo Glucose Sensing Chemical Analysis: A Series of Monographs on Analytical chemistry and Its Applications,” Wiley & Sons, 1 page (2010).
Custodio et al., “A Review on Architectures and Communications Technologies for Wearable Health-Monitoring Systems,” Sensors 12, 13907-13946 (2012).
D29 Medtronic, Paradignm REAL-Time Revel™Minimed, Part 1 132 pages, Part 2 133 pages (2009).
Dexcom, Seven Plus CGMS Users Guide, Part 1, 72 pages, Part 2, 72 pages (2008).
D'Imporzano, Dr., “Reaching More of the World,” Johnson & Johnson Celebrating 125 Years, Annual Report 2010, 2 pages.
Ericksen et al., “Orthospinology Procedures, An Evidence-Based Approach to Spinal Care,” 6 pages (2007).
FreeStyle Navigator® CGMS Indications for Use, 96 pages (2008) G7 User Guide, Instructions for Use, 174 pages (2024).
G7 User Guide, Instructions for Use, 174 pages (2024).
“GlucoWatch® G2™M Biographer (GW2B) Alarm Reliability During Hypoglycemia in Children,” Diabetes Technol Thee., 6(5): 559-566, 12 pages (Oct. 2004).
Hashimoto et al., “Examination of Usefulness of Color Indicator Function of OneTouch Ultra VueTM, Medicine and Pharmacy,” D44-D43, Opposition EP 3 988 471 B1, Hoffmann Elite, 9 pages (with English Translation) (2010).
Huizinga et al., “Automated Defect Prevention, Best Practices in Software Management,” 6 pages (2007).
IEEE 100 The Authoritative Dictionary of IEEE Standards Terms, Seventh Ed., “authentication”, 3 pages (2000).
Letter to Bob Shen at Dexcom, Inc. dated May 15, 2023, Fda U.S. Food & Drug Administration, 8 pages.
Medronic, Guardian REAL-Time, User Guide CGMS, 181 pages (2006).
Medronic, The MiniMed Paradigm® Real-Time System, Insulin Pump and CGMS, 8 pages (2008).
Medronic, The MiniMed Paradigm® Real-Time Insulin Pump User Guide, Paradigm® 522 and 722 Insulin Pumps, 176 pages (2006).
Medronic, The MiniMed Paradigm® Real-Time Sensor Features User Guide, Paradigm® 522 and 722 Insulin Pumps, 76 pages (2006).
Medronic, Paradigm® Real-Time. Revel IM Insulin PumpUser Guide, 132 pages (2009).
Mosa et al., “A Systematic Review of Healthcare Applications for Smartphones,” BMC Med Informatice and Secision Making, 32 pages (2012).
Motorola, Microsoft Applications for Windows Mobile 6 User Guide, 184 pages (2008).
Newton, Newton's Telecom Dictionary, 30th Upldated, Expanded, Aniversry Ed., “authenticate”, 4 pages (2016).
OneTouch Handling Instructions, For self-examination glucose meter, Part 1—36 pages, Part 2—36 pages, Part 3—36 pages (with English Translation 6 pages) (2018).
OneTouch Ultra VueTM, 3 pages (2010).
Section 7 Calibrate Your System/Test Blood Glucose Manually, 65 pages (2008).
Section 10 Response to Alarms, Errors, and Problems, 96 pages (2008).
Seven Plus continuous glucose monitoring system User's Guide, Dexcom, 72 pages (2008).
Seven Plus Glucose Monitoring System Users Guide, Dexcom, 144 pages (2008).
Sommerville, “Software Engineering,” 7 pages (2007).
Stone et al., “User Interface Design and Evaluation,” The Open University, 4 pages (2005).
Stone et al., “User Interface Design and Evaluation,” The Open University, 153 pages (2005).
Stoodley et al., “The Automatic Detection of Transients, Step Changes and Slope Changes in the Monitoring of Medical Time Series,” The Statistician, vol. 28 No. 3, 163-170 (1979).
Wiklund, “Medical Device and Equipment Design,” 6 pages (1995).
Select pages from OneTouch Ultra Vue User Manual published on Oct. 1, 2009 (with English Translation), 4 pages.

Related Publications (1)

	Number	Date	Country
	20230200753 A1	Jun 2023	US

Provisional Applications (1)

	Number	Date	Country
	61113211	Nov 2008	US

Continuations (5)

	Number	Date	Country
Parent	17688761	Mar 2022	US
Child	18177383		US
Parent	17412436	Aug 2021	US
Child	17688761		US
Parent	15675643	Aug 2017	US
Child	17412436		US
Parent	14997463	Jan 2016	US
Child	15675643		US
Parent	12616129	Nov 2009	US
Child	14997463		US

Alarm characterization for analyte monitoring devices and systems

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract